The gut–brain connection: microbes’ influence on mental health and psychological disorders

The human gut microbiome has emerged as a pivotal modulator of brain function and mental health, acting through intricate bidirectional communication along the gut–brain axis. Mounting evidence suggests that microbial communities influence neurodevelopment, neurotransmission, and behavior via pathways involving the vagus nerve, immune signaling, and microbiota-derived metabolites such as short-chain fatty acids and neurotransmitter precursors. This review critically examines the mechanistic underpinnings of microbiota–brain communication and evaluates current findings linking dysbiosis to psychiatric conditions, including depression, anxiety, schizophrenia, autism spectrum disorder, and bipolar disorder. In addition, it assesses the therapeutic potential of microbiome-targeted interventions—such as probiotics, fecal microbiota transplantation (FMT), and precision dietary modulation—in ameliorating neuropsychiatric symptoms. While the field holds considerable promise, limitations, including correlational study designs, small sample sizes, and a lack of standardized methodologies, underscore the need for rigorous, large-scale clinical trials. A deeper understanding of host–microbe interactions may catalyze a paradigm shift in psychiatric treatment, paving the way for novel, personalized microbiome-based therapeutics.

1 Introduction

The human body hosts trillions of microorganisms, collectively known as the microbiome, which are essential for maintaining physiological balance (Patel, 2021). While their roles in digestion and immunity are well established, emerging research indicates that microbes also significantly influence brain function and behavior, with increasing implications for mental health (Singh et al., 2022). A growing body of research suggests that the microbiome plays a significant role in mental health, potentially affecting mood, cognitive function, and even the risk of developing neurological disorders (Smith and Wissel, 2019). The gut–brain network (Figure 1) a complex bidirectional communication network linking the gastrointestinal system and the central nervous system, has recently emerged as a key area of interest in the fields of neuroscience and psychiatry. The gut–brain axis involves multiple pathways, including neural, hormonal, and immune signaling, which collectively influence brain function, emotional regulation, and overall mental health (Mayer et al., 2022). As researchers delve deeper into this dynamic relationship, there is growing recognition of how the gut microbiota may contribute to neurological and psychiatric conditions, opening doors to novel therapeutic approaches (Bhatia et al., 2023). Psychological disorders, including depression, anxiety, schizophrenia, and autism spectrum disorder (ASD), have been increasingly linked to imbalances in the gut microbiota, a phenomenon known as dysbiosis (Meng et al., 2020). Research indicates that disruptions in gut microbial community diversity, bacterial abundance and composition can trigger a cascade of physiological changes, including heightened neuroinflammation, increased oxidative stress, and imbalances in neurotransmitter signaling—factors that are closely associated with the development and progression of psychiatric illnesses (Belizário et al., 2018). Mechanistically, compositional shifts often reduce populations of short-chain fatty acids (SCFA)-producing and barrier-supporting taxa while enriching endotoxin-producing groups; this imbalance can compromise intestinal barrier integrity and increase translocation of microbial products (e.g., lipopolysaccharide) and atypical metabolites into the circulation. These peripheral signals activate systemic immune pathways, promote microglial priming and neuroinflammation, increase oxidative stress, and alter host metabolic routing of precursors (e.g., tryptophan → kynurenine), all of which may perturb neurotransmitter systems and neuroplasticity. Importantly, the directionality of these associations remains unresolved: causal inference in humans is limited by the predominance of cross-sectional studies, although experimental approaches such as fecal microbiota transfer in animal models and a small number of longitudinal and interventional studies provide partial evidence that microbiota alterations can drive behavioral and neurochemical changes. Thus, while mechanistic pathways linking dysbiosis to brain physiology are increasingly well characterized, further longitudinal and controlled human studies are required to establish causality (Chelakkot et al., 2018; An et al., 2022). Conversely, growing evidence suggests that targeted interventions aimed at restoring microbial “balance”, such as probiotics, prebiotics, and dietary modifications, may help with dysbiosis and offer promising therapeutic strategies for enhancing mental well-being and mitigating symptoms of neuropsychiatric disorders (Meher et al., 2024; Zhou et al., 2024).

Figure 1

Figure 1. The gut–brain axis. The gut–brain axis involves communication between the gastrointestinal tract and the brain, influencing emotional and physiological processes through microbial balance and nutrient delivery.

An emerging area of interest in microbiome research is its role in early brain development and lifelong mental health. Studies suggest that the composition of the gut microbiota is shaped from birth and continues to evolve in response to diet, the environment, and lifestyle (Rodríguez et al., 2015). Disruptions during critical developmental periods—such as birth by cesarean section, lack of breastfeeding, antibiotic use, or early-life stress—have been linked to an increased risk of neuropsychiatric disorders later in life (Cho, 2021; Green et al., 2025). For example, research has shown that germ-free mice exhibit exaggerated stress responses and cognitive deficits, reinforcing the idea that the microbiome is essential for normal brain development and function (Luczynski et al., 2016). Understanding how microbial communities establish and influence neurodevelopment could open new avenues for early interventions aimed at preventing or treating disorders that often coincide with mental health challenges.

This review seeks to provide an overview of the intricate and dynamic relationships between the microbiome and psychological disorders, shedding light on the wide range of ways in which microbes may influence brain function and mental health. The underlying mechanisms through which the gut microbiota impacts development, neurological processes, and progression of various psychiatric conditions will be examined, highlighting the potential for promising novel, microbiome-based therapeutic strategies in this field.

2 Interactions between the gut microbiome and the nervous system

The microbiome and nervous system (Figure 2) communicate through the gut–brain axis, influencing mood, cognition, and behavior. Gut microbes have been shown to directly or indirectly impact neurotransmitters, inflammation, the immune system and neural signaling, ultimately having the potential to impact mental health and neurological function.

Figure 2

Figure 2. The microbiome and nervous system. (A) Major microbial groups influencing health; (B) Bidirectional communication between gut microbes and the brain; (C) Gut–brain signaling via the vagus nerve and intestinal barrier; (D) Microbial modulation of neurotransmitters; (E) Role of microbial metabolites, including SCFAs and tryptophan derivatives, in mood regulation.

2.1 Microbiome

The gastrointestinal tract harbors trillions of microbial cells that produce key metabolites such as SCFAs and vitamins, which contribute to digestion, immune regulation, and gut barrier integrity (Lipski, 2020; Lee et al., 2022). These microbes’ impact metabolic functions and produce essential biomolecules that include SCFAs, vitamins such as menaquinone (vitamin K2), a bacterially produced form of vitamin K2 (Ellis et al., 2021), and neurotransmitters that contribute to the maintenance of the integrity of the gut barrier. Some clinical studies have suggested that supplementation with vitamin K2 may play a role in the treatment of depression, potentially through its involvement in anti-inflammatory and neuroprotective pathways (Liu et al., 2022; Tarkesh et al., 2022; Wang S.-T. et al., 2024). Notably, certain gut microbiota species can produce vitamin K2 within the colon, suggesting that microbiome composition may indirectly influence neurological health by contributing to the local synthesis of neuroactive vitamins. Therefore, a healthy microbiome is characterized by diversity and balance, and disruptions—commonly referred to as dysbiosis—have been linked to various health conditions (Fassarella et al., 2021).

2.2 Nervous system: structure and function

The nervous system, which is composed of central and peripheral branches, plays a central role in regulating behavior, cognition, and vital physiological processes (Sabina et al., 2024). Increasing evidence highlights a strong, bidirectional relationship between the nervous system and the gastrointestinal tract, known as the gut–brain axis (Arneth, 2018). This connection is mediated by complex signaling networks involving the vagus nerve, neurotransmitters, immune signals, and microbial metabolites produced in the gut. The enteric nervous system, often referred to as the “second brain,” operates semi independently but remains in constant communication with the brain, allowing gut microbes to influence neural processes such as mood regulation, stress response, and neurodevelopment (Garzone et al., 2025). Understanding this dynamic interaction offers critical insights into how the gut microbiota may contribute to both neurological and psychological conditions. Bidirectional communication between the gut and the brain is facilitated by signaling pathways involving electrical impulses; neuroactive compounds such as serotonin, dopamine, and gamma-aminobutyric acid (GABA); and immune modulators such as cytokines and SCFAs, which are bacterial products. Gut–brain communication occurs through multiple interconnected pathways, including the vagus nerve, the immune system, microbial metabolites such as SCFAs, and endocrine signaling. These mechanisms enable the gut microbiota to influence neural activity, mood regulation, and stress responses. Immune signaling plays a key role in this axis, as the gut microbiota regulates systemic inflammation and immune cell activity, which can in turn affect brain function. This complex neurochemical and immunological crosstalk—often referred to as the gut–brain–immune axis—is a fundamental component of host physiology, highlighting the biological relevance of microbial communication beyond the gut.

2.3 Communication via the vagus nerve

The vagus nerve, the longest cranial nerve in the body, serves as a key communication pathway between the gut and the brain (Wang Y. et al., 2024). The vagus nerve enables bidirectional signaling between the gut microbiota and the CNS, allowing microbial activity to influence brain function and behavior (Liu and Forsythe, 2021). While vagus nerve stimulation has been shown to alleviate symptoms of depression and anxiety, it is not direct evidence of microbiome involvement (Karemaker, 2022). However, preclinical studies suggest that the vagus nerve may serve as a key communication route by which gut microbes influence brain function, linking microbial signals to neural and emotional regulation (Kong et al., 2018). In addition, certain probiotic strains—often termed “psychobiotics”—can modulate the gut microbiota composition and metabolic activity, enhancing the production of neuroactive compounds such as GABA, serotonin precursors, and SCFAs. These metabolites interact with enteroendocrine and epithelial receptors in the gut, stimulating afferent signaling via the vagus nerve and enteric nervous system (ENS) (Smith et al., 2021; Deng et al., 2024). Animal studies have demonstrated that the effects of probiotics on mood and behavior are abolished after subdiaphragmatic vagotomy, confirming this neural route (Needham et al., 2022). Metabolites such as SCFAs also act through free fatty acid receptors (e.g., FFAR2/3), modulating microglial activation, neuroinflammation, and neurotransmitter systems, further influencing emotional regulation (Mishra et al., 2020). Finally, these microbial signals may help restore stress axis balance by reducing hypothalamic pituitary adrenal (HPA) axis hyperactivity and proinflammatory cytokines—effects supported by rodent and early human clinical trials (Rusch et al., 2023).

2.4 Gut microbiota and neurotransmitters

Gut microbes play pivotal roles in the production and regulation of neurotransmitters—chemical messengers that influence mood, cognition, and behavior (Mittal et al., 2017). Several key neurotransmitters are either synthesized directly by gut bacteria or modulated through microbial activity:

2.4.1 Serotonin

Approximately 90% of the body’s serotonin—a neurotransmitter essential for regulating mood, cognition, and emotional behavior—is synthesized in the gastrointestinal tract. Resident gut bacterial strains, notably Lactobacillus and Bifidobacterium, play important roles in modulating serotonin levels by affecting the metabolism of tryptophan, the primary precursor of serotonin (Corano Scheri et al., 2017; Jeong et al., 2021). These bacteria can shift tryptophan away from the kynurenine pathway—often activated under stress and inflammation—towards the serotonergic pathway, increasing peripheral serotonin synthesis (Correia and Vale, 2022). Moreover, tryptophan metabolism by gut microbes involves the enzymatic activity of tryptophanase, which converts tryptophan into indole and related metabolites. Importantly, indole compounds have been shown to influence host neuroendocrine pathways, immune modulation, and intestinal barrier integrity (Ye et al., 2022). Furthermore, indole and its derivatives are implicated in the regulation of biofilm formation in gram-negative bacteria (Minvielle et al., 2013), thereby affecting microbial colonization and the ecological balance of the gut (Ye et al., 2022). These biochemical pathways also interact with the synthesis of other critical neuroactive compounds, such as dopamine and tyrosine-derived catecholamines (described below). Disruptions in the production and regulation of these compounds can lead to neurochemical imbalances associated with various neuropsychiatric conditions (Stasi et al., 2019; Simpson et al., 2021). For example, indole-3-propionic acid (IPA), a tryptophan-derived microbial metabolite, has been shown to exert neuroprotective effects by reducing oxidative stress and modulating inflammatory responses in the brain (Konopelski and Mogilnicka, 2022; Kim et al., 2023). Reduced levels of IPA have been observed in patients with depression and stress, suggesting that diminished microbial production of protective indole derivatives may contribute to the pathophysiology of these disorders (Konopelski and Mogilnicka, 2022; Mu et al., 2025). Thus, the interplay between microbial tryptophan metabolism and host neurotransmitter systems appears to be at a connection between the gut microbiota and mental health outcomes.

2.4.2 Dopamine

Dopamine is associated with motivation, reward, and emotional regulation and is influenced by CNS activity as well as the metabolic capacity of the gut microbiota. Although dopamine itself cannot cross the blood–brain barrier, the gut can produce significant amounts of its biochemical precursors, which may influence systemic physiology and indirectly affect brain function. Several gut-residing bacteria, including Escherichia coli, Bacillus subtilis, Proteus vulgaris, Serratia marcescens, and Staphylococcus aureus, have been shown to produce dopamine or its precursors, particularly tyrosine and L-DOPA (levodopa) (Oleskin et al., 2021; Eicher and Mohajeri, 2022). These precursors are central intermediates in dopamine biosynthesis, with tyrosine hydroxylated into L-DOPA, which is then decarboxylated to form dopamine. Species such as Enterococcus faecalis and Enterococcus faecium express tyrosine decarboxylase enzymes capable of directly converting dietary L-DOPA into dopamine within the gut lumen (Villageliú and Lyte, 2018). This activity has clinical relevance, especially in the context of neurological disorders such as Parkinson’s disease, where gut microbial metabolism can influence the bioavailability of therapeutic L-DOPA—the precursor to dopamine that must cross the blood–brain barrier to affect central nervous system function (Niehues and Hensel, 2009; Van Kessel and El Aidy, 2019). Moreover, microbially derived dopamine can interact with the enteric nervous system, potentially modulating gastrointestinal motility and immune signaling by acting on dopamine receptors expressed on immune cells, such as T cells and macrophages, thereby affecting cytokine production and inflammatory responses within the gut (Levite, 2016; Scott et al., 2024). Overall, alterations in microbial populations that affect dopamine-related pathways may contribute to the severity and progression of neuropsychiatric conditions such as Parkinson’s disease and schizophrenia by influencing neurotransmitter availability and neuroinflammatory processes, highlighting the functional relevance of the gut–brain axis in maintaining mental health. Further research is needed to determine the extent to which these peripheral pathways influence central dopaminergic signaling.

2.4.3 Gamma-aminobutyric acid

GABA is the primary inhibitory neurotransmitter in the CNS; it is crucial for regulating neuronal excitability and is involved in the modulation of anxiety, stress responses, and mood regulation. Emerging evidence indicates that certain gut microbes possess the enzymatic machinery required to synthesize GABA from glutamate via glutamate decarboxylase (GAD). Among the most well-documented GABA-producing strains are Lactobacillus rhamnosus, Lactobacillus brevis, and Bifidobacterium dentium. These microbes are capable of producing GABA within the gut lumen, where it may exert effects locally on the ENS or indirectly via the vagus nerve and subsequently impact the CNS (Tette et al., 2022). Preclinical studies, particularly in murine models, have demonstrated that L. rhamnosus (JB-1) administration alters GABA receptor expression in specific brain regions, such as the amygdala and hippocampus, and that this effect is correlated with reduced anxiety- and depressive-like behaviors (Kochalska et al., 2020; Jarosz et al., 2024). Importantly, these effects were abolished following vagotomy, indicating a crucial role of vagus nerve-mediated communication between the gut and brain in the context of GABA signaling (Liu and Forsythe, 2021). Additionally, microbially derived GABA has been shown to influence intestinal barrier integrity and modulate immune function (Conn et al., 2024). Although GABA itself does not cross the blood–brain barrier in significant amounts (Kakee et al., 2001), the interplay between gut microbial GABA production and the host’s neuroendocrine signaling—particularly the communication between the gut, the HPA axis, and the autonomic nervous system—remains a promising area of investigation, especially in relation to psychobiotics—live organisms that, when ingested in adequate amounts, confer mental health benefits. These findings underscore the therapeutic potential of targeting GABAergic activity through microbiota-based interventions in anxiety, depression, and stress-related disorders.

2.5 Role of gut bacteria-derived vitamins in mental health

Bacterially derived vitamins, particularly those from the B-complex group and vitamin K2, contribute to processes including neurotransmitter synthesis, energy metabolism, and neuroprotection. Emerging research suggests that deficiencies in these vitamins—often influenced by gut dysbiosis—may be linked to mood disorders, cognitive decline, and other psychiatric symptoms. While the underlying mechanisms vary, their importance in supporting brain health is increasingly recognized. A summary of these vitamins, their microbial sources, and mental health relevance—acknowledging that observed deficiencies often reflect overall systemic levels rather than microbiota-specific causes—is provided in Table 1.

Table 1

Table 1. Microbially produced vitamins and their roles in cognitive function and mental health.

2.6 Role of microbial metabolites

In addition to directly influencing neurotransmitters, the gut microbiota produces a variety of metabolites that can impact brain function and mental health. The microbiome metabolome may act as a nexus of body-mind health. Among these metabolites, SCFAs and tryptophan metabolites play particularly significant roles:

● SCFAs, which include acetate, propionate, and butyrate, are key metabolites produced by the gut microbiota through the fermentation of dietary fibers (O'Riordan et al., 2022; Fock and Parnova, 2023). SCFAs can cross the blood–brain barrier (BBB) via monocarboxylate transporters located on endothelial cells. Once in the CNS, they can influence BBB integrity by increasing the expression of tight junction proteins, thereby contributing to the maintenance of the selective permeability of the BBB. This process is critical for preventing neuroinflammation because it limits the passage of peripheral immune mediators into the brain and protects neural tissue from harmful substances (Silva et al., 2020). In addition to their role in BBB maintenance, SCFAs modulate neuroinflammatory responses. They affect glial cell morphology and function, leading to alterations in the levels of neurotrophic factors, which are essential for neurogenesis and neuronal homeostasis. Moreover, SCFAs also contribute to the biosynthesis of neurotransmitters, including serotonin, by influencing the availability of their precursors and modulating the expression of related enzymes (O'Riordan et al., 2022). The impact of SCFAs on the gut–brain axis underscores the importance of considering dietary fiber intake in the context of mental health conditions. By promoting the production of SCFAs, a fiber-rich diet may support BBB integrity, help modulate neuroinflammation, and influence neurotransmitter synthesis, collectively contributing to improved cognitive function and mood regulation.

● Tryptophan metabolism: Tryptophan undergoes diverse microbial and host-driven transformations that extend far beyond serotonin synthesis. These pathways produce metabolites such as kynurenine and indole derivatives, which can influence immune regulation, oxidative stress, and gut–brain signaling, with emerging relevance to neurodevelopment and psychiatric disorders (Bosi et al., 2020). A substantial portion of dietary tryptophan is catabolized via the kynurenine pathway, producing metabolites such as kynurenine, quinolinic acid, and kynurenic acid—compounds that are closely linked to neuroinflammation and depressive disorders (Keszthelyi et al., 2009; Lukić et al., 2022). For example, elevated levels of quinolinic acid, a neurotoxic metabolite, have been observed in patients with major depressive disorder and are thought to contribute to glutamatergic dysregulation and neuronal damage (Busse et al., 2015; Öztürk et al., 2021). The gut microbiota can significantly influence this metabolic routing by shaping the host’s immune environment. Specifically, microbial components such as lipopolysaccharides (LPS) from gram-negative bacteria can activate immune responses and lead to the release of proinflammatory cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) (Michlewska et al., 2009). These cytokines, in turn, increase the activity of indoleamine 2,3-dioxygenase (IDO), a host enzyme that diverts tryptophan metabolism away from serotonin synthesis and toward the kynurenine pathway. This shift results in the production of neuroactive metabolites—such as quinolinic acid and kynurenic acid—which are associated with neuroinflammation, excitotoxicity, and mood dysregulation in individuals with disorders such as depression. Thus, while the microbiota itself may not directly modulate IDO, it influences the immune signals that govern its expression, illustrating the indirect but critical role of microbial–host immune interactions in brain function (Gao et al., 2018; Riazati et al., 2022). Additionally, certain commensal bacteria, such as Lactobacillus reuteri and Clostridium sporogenes, metabolize tryptophan into indoles and their derivatives, such as indole-3-aldehyde, which activate the aryl hydrocarbon receptor (AhR), a pathway involved in immune regulation and neuroprotection (Salminen, 2023). Disruptions in the balance between serotonin synthesis and kynurenine pathway activity can shift the neurochemical environment toward a proinflammatory and neurotoxic state, which has been shown to contribute to cognitive dysfunction, mood disorders, and increased susceptibility to conditions such as depression and schizophrenia (Muneer, 2020; Correia and Vale, 2022). These findings underscore the important connection between microbial tryptophan metabolism and central nervous system function, underscoring its potential importance in mediating mental health.

3 Microbiota and psychological disorders

The influence of the gut microbiota extends beyond digestion and immune function, with a growing body of research showing a link between the microbiota and mental health and neurological function. Growing evidence (Table 2) suggests that dysregulation in the gut microbiome) suggests that gut dysbiosis contributes to the pathophysiology of various psychological disorders. Through mechanisms such as chronic low-grade inflammation (characterized by sustained elevation of proinflammatory cytokines), disruption of neurotransmitter pathways, and immune system dysregulation (including both hyperactive and insufficient immune responses), dysbiosis has been linked to conditions such as depression, anxiety, schizophrenia, ASD, and bipolar disorder. This section explores the relationship between the microbiota and these psychological disorders, shedding light on the potential mechanisms involved.

Table 2

Table 2. Microbiota and psychological disorders.

3.1 Depression and anxiety: dysbiosis, inflammation, and serotonin pathways

Depression and anxiety disorders are among the most prevalent mental health conditions, and a growing number of human studies have identified significant associations among the gut microbiota composition, microbe-targeted interventions, and these disorders. Case–control studies have shown that individuals with depression and anxiety often exhibit increased pro-inflammatory bacteria and reduced SCFA-producing taxa (Liang et al., 2018; Du et al., 2020; Simpson et al., 2021; Mitrea et al., 2022). Studies have demonstrated that individuals with depression often have reduced microbial diversity and depletion of beneficial genera such as Lactobacillus and Bifidobacterium. Notably, FMT experiments have provided compelling causal evidence: when the gut microbiota from depressed human donors or mice subjected to chronic stress are transferred into germ-free or antibiotic-treated rodents, the recipients develop anxiety- and depression-like the behaviors of the donors. These animals also exhibit increased neuroinflammatory markers—such as elevated hippocampal IFN-γ, TNF-α, and IDO1—as well as changes in microbial taxa (e.g., decreased Lactobacillus and increased Bacteroides) that parallel donor profiles (Romijn et al., 2017; Han and Kim, 2019; Jang et al., 2019; Li et al., 2019). This body of evidence strongly supports a link between dysbiosis and behavioral phenotypes and highlights the mechanistic relevance of gut–brain–immune interactions in depression and anxiety.

Inflammation has been strongly implicated in depression and anxiety, with increased levels of proinflammatory cytokines, such as interleukin-6 (IL-6) and TNF-α, observed in affected individuals (Elgellaie et al., 2023). Dysbiosis contributes to this inflammatory state by disrupting immune homeostasis primarily through increased intestinal permeability, which allows bacterial components such as LPS to translocate into the systemic circulation. This translocation triggers a systemic immune response characterized by elevated proinflammatory cytokines, which can, in turn, influence brain function and behavior through signaling along the gut–brain axis (Rutsch et al., 2020). Additionally, a reduction in serotonin-producing microbes can negatively impact mood regulation, potentially contributing to the onset of depressive and anxious symptoms (Sarkar et al., 2020; Li et al., 2025).

3.2 Schizophrenia: gut–brain connection in psychotic disorders

Schizophrenia is a severe psychiatric disorder characterized by hallucinations, delusions, and cognitive impairments (McCutcheon et al., 2023). While its exact cause remains unclear, research suggests that imbalances in the gut microbiota may contribute to disease progression (Ma and Song, 2023). Studies comparing the microbiomes of individuals with schizophrenia to those of healthy controls have revealed significant differences in microbial composition, with an increase in proinflammatory bacteria, including Eggerthella, Lactobacillus, and Veillonella; a decrease in potentially beneficial bacteria, such as Faecalibacterium and Roseburia; and a reduction in beneficial microbes, including Coprococcus and Blautia (Yan et al., 2022; Gokulakrishnan et al., 2023).

The role of the gut microbiota in schizophrenia may be linked to neuroinflammation, oxidative stress, and altered neurotransmitter activity (Carlessi et al., 2021). Gut microbial metabolites, such as SCFAs, have been implicated in schizophrenia through both developmental and symptomatic pathways. Early-life alterations in SCFA production—particularly butyrate production—have been associated with neurodevelopmental changes that may predispose individuals to schizophrenia. Additionally, during the onset of symptoms, reduced SCFA levels have been linked to increased gut permeability, systemic inflammation, and disrupted blood–brain barrier integrity, all of which may contribute to the cognitive and behavioral symptoms characteristic of the disorder (Peng et al., 2022; Kowalski et al., 2023). FMT studies in animal models have demonstrated that transferring gut bacteria from individuals with schizophrenia to germ-free mice induces schizophrenia-like behaviors, further supporting the role of the microbiota in this disorder (Vasiliu, 2023).

3.3 Autism spectrum disorder: early-life microbiota development and behavior

ASD is a neurodevelopmental condition characterized by social communication deficits and repetitive behaviors (Bhat, 2021; Hirota and King, 2023). Mounting evidence suggests that the gut microbiome may play a role in autism, particularly during early development, when the microbiota is still forming (Vuong and Hsiao, 2017; Taniya et al., 2022). Autistic children often exhibit distinct gut microbiota profiles, broadly including reduced microbial diversity and an increased abundance of certain bacterial species, such as Clostridia, which are known to produce neurotoxic metabolites (Fattorusso et al., 2019; Zou et al., 2020).

One potential mechanism linking gut microbes to ASD involves alterations in gut permeability and immune function (Azhari et al., 2019). Studies have reported increased intestinal permeability, or a “leaky gut,” in children with ASD, which may allow bacterial metabolites, bacterial components themselves and inflammatory molecules to enter the bloodstream and affect brain development (Eshraghi et al., 2020; Al-Ayadhi et al., 2021). Additionally, disruptions in the microbial production of neurotransmitters, including GABA and serotonin, may contribute to ASD-related behavioral symptoms (Garcia-Gutierrez et al., 2020; Bamicha et al., 2024). These imbalances may influence excitatory-inhibitory signaling in the brain, potentially contributing to core behavioral symptoms such as social deficits, anxiety, and repetitive behaviors. Emerging interventions, such as probiotic supplementation, dietary modifications and FMT, have shown promise in improving gastrointestinal and behavioral symptoms in autistic children, further highlighting the influence of the microbiota on neurodevelopment (Tan et al., 2021).

3.4 Bipolar disorder: immune–microbiome interactions

Bipolar disorder is a mood disorder characterized by alternating episodes of mania and depression (McIntyre et al., 2020). Recent studies suggest that immune system dysfunction and alterations in the gut microbiota may contribute to the pathophysiology of this disorder (Levy et al., 2017). Individuals with bipolar disorder often exhibit increased levels of systemic inflammation, with elevated concentrations of inflammatory markers such as C-reactive protein (CRP) and IL-6. Dysbiosis may contribute to this inflammatory state by disrupting gut barrier integrity and triggering immune activation (Doney et al., 2022; Zhao N. O. et al., 2022).

In individuals with bipolar disorder, alterations in the gut microbial composition have been linked to dysregulation of serotonin and dopamine pathways—neurotransmitter systems that are central to mood stabilization and are commonly disrupted during manic and depressive episodes (González-Arancibia et al., 2019). Additionally, preliminary research suggests that probiotic supplementation may help reduce inflammation and stabilize mood symptoms in individuals with bipolar disorder, opening new avenues for microbiome-targeted therapeutic strategies (Zeng et al., 2022). These effects are thought to arise through several interconnected mechanisms: by enhancing gut barrier integrity and thereby reducing leaky gut, by downregulating proinflammatory cytokine production and modulating immune responses, and by influencing the synthesis and availability of key neurotransmitters such as serotonin, dopamine, and GABA—each of which plays a crucial role in mood regulation. Together, these pathways highlight the therapeutic potential of targeting the gut microbiome in the management of bipolar disorder (Borkent et al., 2025; Zeng et al., 2022).

3.5 Gut microbiota and obsessive-compulsive disorder

Although research on the gut microbiota in patients with OCD is still in its early stages, emerging evidence suggests a meaningful connection between microbial composition and OCD symptomatology (Turna et al., 2016). Clinical studies have revealed a reduction in microbial diversity among individuals with OCD, particularly a decrease in beneficial butyrate-producing genera such as Oscillospira, Anaerostipes, and Odoribacter, which are known to play key roles in maintaining gut barrier integrity and anti-inflammatory signaling (Turna et al., 2020). Concurrently, an increased abundance of proinflammatory taxa such as Rikenellaceae—notably Alistipes—has been reported, indicating a shift toward a more inflammatory microbial profile (Parker et al., 2020; Tavella et al., 2021). These microbial alterations may contribute to increased intestinal permeability and systemic inflammation, both of which have been implicated in neuropsychiatric disorders. In support of a potential causal role, FMT from individuals with OCD into germ-free mice has been shown to induce compulsive-like behaviors and alter neurochemical pathways in recipient animals, including elevated succinic acid levels associated with neuroinflammatory responses (Zhang et al., 2024). In preclinical models, probiotic treatment with Lactobacillus casei Shirota has been found to attenuate compulsive grooming behavior in rodents, normalize BDNF expression, and modulate serotonin receptor levels, showing comparable effects to those of fluoxetine—a standard pharmacological treatment for OCD (Sanikhani et al., 2020). Collectively, these findings suggest that gut dysbiosis may contribute to the pathophysiology of OCD through immune modulation, microbial metabolite production, and effects on neurotransmitter systems. While human studies remain limited, this growing body of literature points to the gut microbiome as a promising target for future therapeutic interventions in patients with OCD.

3.6 Gut microbiota and post-traumatic stress disorder

Animal and preliminary human studies increasingly suggest that PTSD may involve disturbances in the gut microbial composition, intestinal barrier integrity, and downstream neuroimmune and neurochemical signaling. In a mouse model of repeated social defeat stress (RSDS), which induces PTSD-like behaviors, researchers reported significant gut dysbiosis, reduced gut microbial diversity, and disrupted barrier function characterized by altered tight junction proteins and increased permeability (He et al., 2024; Voigt et al., 2025). These mice also exhibited a proinflammatory gut milieu, supporting the hypothesis that repeated trauma induces a cascade from microbial imbalance to systemic immune activation (Yadav et al., 2023).

In humans, systematic reviews comparing PTSD patients to trauma-exposed controls have linked the reduced abundance of protective taxa—such as Actinobacteria, Lentisphaerae, and Verrucomicrobia—with PTSD symptom severity (Winder et al., 2025). Studies of specific populations, such as firefighters, revealed that individuals without PTSD symptoms presented greater gut microbial diversity and higher levels of SCFA-producing species, such as Alistipes putredinis, which has been associated with resilience to stress (Yoo et al., 2025). Therapeutically, pilot human trials using prebiotic supplementation in veterans with PTSD revealed modest increases in SCFA-producing bacteria and reductions in pro-inflammatory taxa, along with attenuated stress responses and trends toward decreased symptoms (Voigt et al., 2025). In rodent experiments, the administration of Lactobacillus reuteri DSM 17938 improved intestinal integrity, reduced systemic inflammation (e.g., lowered CRP), and reversed reductions in cortical BDNF linked to PTSD-like behaviors (Petakh et al., 2024). A separate mouse model using single prolonged stress (SPS) revealed that probiotic treatment mitigated anxiety- and depression-like behaviors, restored BDNF expression, and improved gut morphology (Khan et al., 2025).

Together, these findings suggest that PTSD may be associated with gut dysbiosis, increased intestinal permeability, and systemic inflammation—factors through which microbial metabolites and immune signaling influence neurobiology and behavior. While causal human data remain limited, these studies support the potential for microbiome-based adjunctive therapies in PTSD patients.

4 Mechanisms of influence

The gut microbiota influences mental health through multiple interconnected pathways, including immune regulation and stress response modulation (Merlo et al., 2024). These mechanisms help explain how microbial composition affects brain function, behavior, and psychological well-being. Disruptions in these pathways due to dysbiosis can contribute to the development and progression of various mental health disorders. This section explores the key mechanisms by which the microbiota influences the brain and mental health, as illustrated in Figure 3.

Figure 3

Figure 3. Mechanisms linking the gut microbiota to brain function and mental health. Microbial metabolites such as SCFAs and GABA, as well as serotonin and cytokines, affect neurometabolite production, immune activation, and endocrine responses through gut–brain communication.

4.1 Inflammation and immune modulation

The immune system plays a critical role in maintaining brain health, and the gut microbiota is an important regulator of immune function. A balanced microbiome supports immune homeostasis, whereas dysbiosis can trigger chronic low-grade inflammation, which has been implicated in several neuropsychiatric disorders, including depression, schizophrenia, and bipolar disorder (Mundula et al., 2022; Perdijk et al., 2024).

Microbial metabolites, such as SCFAs, help regulate inflammation by influencing immune cells (Parada Venegas et al., 2019). However, an imbalance in gut bacteria can lead to increased intestinal permeability, allowing inflammatory molecules such as LPS, which are components of the outer membrane of gram-negative bacteria and potent immune activators, to enter the bloodstream (Candelli et al., 2021). These proinflammatory signals can activate microglia, the brain’s immune cells, leading to neuroinflammation and contributing to cognitive and emotional disturbances (Qin et al., 2007; Skrzypczak-Wiercioch and Sałat, 2022). Peripheral immune mediators, such as cytokines and LPS, can cross the blood–brain barrier when its integrity is compromised or can signal indirectly via the vagus nerve and endothelial cells lining the cerebral vasculature (Huang et al., 2021).

Moreover, certain bacterial species modulate the production of anti-inflammatory cytokines (e.g., interleukin-10) and proinflammatory cytokines (e.g., interleukin-6, tumor necrosis factor-alpha), further influencing brain function (Strle et al., 2001). Chronic inflammation has been linked to alterations in neurotransmitter signaling, oxidative stress, and impaired neuroplasticity, all of which are associated with mental health disorders (Hassamal, 2023). Studies have shown that certain gut bacteria modulate the production of anti-inflammatory cytokines—such as interleukin-10 (IL-10)—as well as proinflammatory cytokines, including IL-6 TNF-α, which can significantly influence brain function (Steen et al., 2020). For example, Faecalibacterium prausnitzii is known to increase IL-10 secretion while simultaneously inhibiting NF-κB activation, thereby suppressing the production of inflammatory cytokines (IL-6 and TNF-α) (Alameddine et al., 2019). Conversely, dysbiosis characterized by an increased abundance of gram-negative taxa elevates LPS levels and stimulates immune responses that increase systemic IL-6 and TNF-α, both of which are markers linked to mood disorders such as depression and anxiety (Chen et al., 2024). Elevated IL-6 has also been shown to repress BDNF expression via epigenetic mechanisms in the brain, leading to impaired neuroplasticity and emotional regulation (Jehn et al., 2015). Collectively, these findings support the concept that microbial modulation of cytokine profiles—through both anti- and proinflammatory pathways—can induce neuroimmune changes directly associated with mental health outcomes.

4.2 Stress response and the HPA axis

The gut microbiota is a key modulator of the body’s response to stress, primarily through its interaction with the HPA axis (Rusch et al., 2023). The HPA axis regulates the body’s stress response system by controlling the release of cortisol, a hormone involved in mood regulation, energy metabolism, and immune function (Dedovic et al., 2009). In terms of mood regulation, persistent activation of the HPA axis—common in chronic stress—can lead to elevated cortisol exposure. Chronic cortisol elevation damages brain regions such as the hippocampus and prefrontal cortex, which are important for emotional regulation and cognitive control; this damage contributes to mood disturbances and depressive symptoms (Bertollo et al., 2025). With respect to immune function, cortisol exerts both acute anti-inflammatory effects and, under prolonged exposure, paradoxical immune dysregulation. While it suppresses proinflammatory cytokines (e.g., IL-6 and TNF-α) and dampens T-cell activity in the short term, chronic cortisol elevation may impair immune cell responsiveness and promote a shift toward Th2 dominance, reducing cellular immunity and increasing susceptibility to infections (Alotiby, 2024). Importantly, the gut microbiota and immune signals influence the HPA axis: microbial components such as LPS and elevated cytokines (e.g., IL-6) can activate the axis, increasing cortisol levels (Liu and Zhu, 2018; Bertollo et al., 2025).

Beneficial gut bacteria, such as Lactobacillus and Bifidobacterium, have been shown to modulate the stress response by reducing cortisol levels and promoting the production of GABA, an inhibitory neurotransmitter that helps counteract stress-induced excitability (Liu and Zhu, 2018; Tette et al., 2022; Zhao N. et al., 2022). Conversely, an imbalance in gut microbes can increase the release of stress hormones, increasing susceptibility to anxiety and depression-like behaviors (Nie et al., 2024).

Animal studies have demonstrated that germ-free mice exhibit exaggerated HPA axis responses to stress, further highlighting the role of the microbiota in stress regulation. Restoring beneficial microbes through probiotic supplementation has shown potential for modulating stress hormone levels and enhancing behavioral resilience, particularly in populations with HPA axis dysregulation. For example, in a murine model colonized with microbiota from patients with Cushing’s disease—a condition characterized by excessive cortisol production—probiotic intervention attenuated depression- and anxiety-like behaviors and normalized corticosterone levels. Similarly, human and preclinical studies have demonstrated that specific probiotic strains can influence the microbiota–gut–brain axis, thereby regulating cortisol output and improving stress-related outcomes (Wiley et al., 2017; Nie et al., 2024).

4.3 Effects of diet, probiotics, and prebiotics on mental health

Diet plays a crucial role in shaping the gut microbiome, which in turn influences mental health. Nutritional components such as fiber, polyphenols, and omega-3 fatty acids contribute to a balanced microbiota, supporting brain function and emotional well-being (Businaro, 2022). In contrast, diets high in saturated fats and refined sugars have been linked to dysbiosis, increased inflammation, and a greater risk of neuropsychiatric disorders (Leo and Campos, 2020).

Probiotics have been shown to positively impact brain function when this results in colonization in the gut. Specific probiotic strains, such as Lactobacillus rhamnosus and Bifidobacterium longum, help regulate neurotransmitter levels, particularly serotonin and GABA, and have been shown to be associated with reduced symptoms of depression and anxiety (Jarosz et al., 2024). These probiotics also play a role in reducing neuroinflammation, further supporting mental well-being (Meher et al., 2024).

Prebiotics, on the other hand, are nondigestible dietary fibers that serve as fuel for beneficial gut bacteria (Rezende et al., 2021). Compounds such as inulin and fructo-oligosaccharides promote the growth of bacteria that produce SCFAs (Birkeland et al., 2020), which have neuroprotective and anti-inflammatory properties. By fostering a healthier gut environment, prebiotics indirectly contribute to improved cognitive function and emotional stability. For example, Schmidt et al. reported that healthy volunteers who consumed galacto oligosaccharides (GOS) daily for three weeks presented a reduced cortisol awakening response and decreased attentional vigilance to negative stimuli, suggesting an anxiolytic effect (Schmidt et al., 2015). Similarly, a randomized controlled trial by Kato-Kataoka et al. demonstrated that prebiotic-containing fermented milk improved stress-related symptoms and sleep quality in medical students under academic stress (Kato-Kataoka et al., 2016).

Dietary patterns also play a significant role in mental health (Grajek et al., 2022). The Mediterranean diet—characterized by high intake of fiber, polyphenols, omega-3 fatty acids, and fermented foods—promotes microbial diversity and increases the abundance of beneficial taxa such as Bifidobacterium and Lactobacillus, as well as SCFA-producing species such as Faecalibacterium prausnitzii (Ghosh et al., 2020; Ventriglio et al., 2020). These microbial shifts are associated with reduced intestinal inflammation and improved blood–brain barrier integrity, both of which support cognitive function and emotional regulation (Jacka et al., 2017). In contrast, a Western diet—high in saturated fats, refined sugars, and low in fiber—has been shown to reduce microbial diversity and promote the expansion of proinflammatory bacteria such as Bilophila wadsworthia and Alistipes (David et al., 2014; Zhang et al., 2023). These findings highlight the importance of dietary interventions in promoting both gut and brain health, emphasizing the potential for nutritional strategies to help promote a healthy gut microbiome as a complementary treatment approach for managing psychological disorders.

5 Therapeutic potential

Growing evidence suggests that targeting the gut microbiome may provide novel therapeutic strategies for psychological disorders. Interventions such as probiotics, FMT, and diet-based approaches aim to restore microbial balance, reduce neuroinflammation, and regulate neurotransmitter production. These therapies have potential for improving symptoms of depression, anxiety, schizophrenia, and other mental health conditions.

5.1 Probiotics and psychobiotics

Probiotics have been studied for their role in mental health because of their ability to influence neurotransmitter production and regulate the immune response. Some probiotics, known as psychobiotics, have been shown to have specific effects on brain function by modulating serotonin, dopamine, and GABA levels (Sharma et al., 2021).

Psychobiotics also influence the HPA axis, which regulates the body’s response to stress. By promoting a balanced stress response and reducing cortisol levels, these beneficial microbes may help alleviate mood disorders (Bermúdez-Humarán et al., 2019). Clinical studies suggest that probiotic supplementation can improve emotional well-being, although its efficacy depends on factors such as strain specificity, dosage, and an individual’s baseline microbiome composition (Pirbaglou et al., 2016).

5.2 Diet-based interventions

The consumption of fiber-rich foods, fermented products, and essential nutrients such as omega-3 fatty acids can help maintain microbial balance and promote the production of beneficial metabolites (Nogal et al., 2021). Prebiotic-rich foods, including those containing inulin and fructo-oligosaccharides, provide nourishment for beneficial bacteria, stimulating their growth and increasing the production of SCFAs, which have neuroprotective and anti-inflammatory effects (Bornet and Brouns, 2002).

Additionally, certain dietary compounds, such as polyphenols found in plant-based foods, have been shown to support brain function by modulating gut bacteria and reducing oxidative stress (Shanmugam et al., 2022). Emerging research highlights the role of personalized nutrition in mental health, emphasizing the need for tailored dietary recommendations on the basis of an individual’s microbiome composition (Bianchetti et al., 2023).

6 Impact of antibiotic use and misuse on mental health

While antibiotics have been instrumental in combating infectious diseases, their overuse and misuse have raised significant concerns, particularly regarding gut microbiota disruptions and their subsequent effects on health. Antibiotics can dramatically alter the composition and diversity of the gut microbiota, leading to dysbiosis, which has cascading effects on neurodevelopment, behavior, and cognitive function (Dahiya and Nigam, 2023).

Dysbiosis induced by antibiotics leads to a reduction in beneficial bacteria and disrupts the production of neuroactive compounds such as SCFAs, GABA, serotonin, and dopamine, which are vital for supporting mental health (Guida et al., 2018; Bibi et al., 2025). Disruption of key microbial pathways—such as those involved in the synthesis of SCFAs, tryptophan metabolites, and neuroactive compounds such as GABA and serotonin—can impair neurotransmission and neuroplasticity. This microbial dysregulation has been associated with increased vulnerability to anxiety, depression, and cognitive decline through mechanisms involving heightened neuroinflammation, oxidative stress, and altered brain-derived neurotrophic factor (BDNF) signaling (Kelly et al., 2015; Dinan and Cryan, 2017; Mohajeri et al., 2018). Notably, early-life exposure to antibiotics is especially important. The first year of life represents a critical window for the establishment of a healthy gut microbiome and brain development (Fox et al., 2022). Several studies have shown that antibiotic exposure during this period is associated with an increased risk of behavioral problems and poorer cognitive outcomes later in childhood (Slykerman et al., 2023). Furthermore, large-scale population studies have identified links between early antibiotic use and increased risk of psychiatric disorders, including depression and anxiety, later in life (Lavebratt et al., 2019).

The mechanisms underlying these effects are multifaceted. Antibiotics can increase intestinal permeability (“leaky gut”), allowing microbial components or stimulating peripheral inflammation to enter systemic circulation and influence brain function (Chancharoenthana et al., 2023). In parallel, antibiotics may also modulate the HPA axis by disrupting the gut microbiota, which plays a key role in regulating stress responses. Such microbial disturbances can impair the production of microbial metabolites (e.g., SCFAs), reduce anti-inflammatory signaling, and increase gut permeability—ultimately leading to heightened activation of the HPA axis and potential neuroendocrine imbalances (Wu et al., 2020). Given these concerns, it is crucial to adopt judicious antibiotic use, especially during infancy and childhood. Clinical approaches should weigh the therapeutic benefits of antibiotics against potential long-term consequences for health. Furthermore, probiotic supplementation during or after antibiotic therapy is being explored as a strategy to restore microbiome balance and mitigate neuropsychiatric risk (Arslanova et al., 2021; Thabet et al., 2024).

7 Future directions and challenges

While research on the role of the gut microbiome in mental health has shown promise, significant challenges remain in translating these findings into effective clinical applications. Many studies rely on small sample sizes, animal models, or correlational designs, which limits the ability to draw causal conclusions about the efficacy of microbiome-targeted interventions. While concerns about long-term safety are particularly relevant for more invasive approaches, such as FMT, less invasive strategies, such as probiotics, are generally regarded as safe and may offer a favorable risk profile compared with conventional pharmacological treatments. Alterations in the composition of the gut microbiota have been consistently observed across various psychiatric disorders, including depression, anxiety, schizophrenia, ASD, and bipolar disorder. These changes are often characterized by reduced microbial diversity, increased abundance of proinflammatory taxa, and depletion of beneficial microbes.

While the observable associations between gut dysbiosis and mental health disorders are robust, the question of whether microbial alterations cause neurological symptoms or are secondary to them remains a critical knowledge gap in the field. Traditional cross-sectional and case-control studies dominate the literature, thereby limiting our capacity to infer true causality. Recent advances, however, offer promising routes toward disentangling directionality. For example, a Mendelian randomization (MR) study analyzing genome-wide data for gut microbiota taxa and psychiatric disorders identified bidirectional causal relationships: specific genera (e.g., Bacteroides, Marvinbryantia) influenced brain structure and psychiatric risk, while certain brain-region changes fed back to alter microbiota composition (Ye et al., 2025). Additionally, systematic reviews of FMT interventions have found that transferring microbiota from depressed or anxious humans into animals frequently induces behavioral changes consistent with mood disorders, suggesting that microbial composition can drive aspects of psychopathology (Chinna Meyyappan et al., 2020).Nonetheless, the repeated observation of distinct microbial signatures across different conditions supports the relevance of the gut–brain axis in psychiatric disease and underscores the need for longitudinal and mechanistic research to clarify causality. Advanced techniques such as metagenomics, metabolomics, and multi-omics approaches may help uncover the precise mechanisms underlying the gut–brain connection, allowing for more targeted therapeutic strategies. For example, a multi-omics study in first-episode schizophrenia patients revealed associations between microbial taxa, altered plasma metabolites (including GABA, tryptophan derivatives, and SCFAs), and disruptions in brain network connectivity, providing mechanistic insight into gut-to-brain signaling pathways (Wang Z. et al., 2024). Moreover, in patients with bipolar depression, concurrent fecal metagenomic profiling and serum metabolomics identified microbe-derived neuroactive compounds—such as kynurenic acid, B-vitamins, and GABA—that are correlated with changes in brain functional connectivity linked to mood regulation (Li et al., 2022). Additionally, the metabolomics of moderate–large cohorts with major depressive disorder has revealed dysregulated metabolites (e.g., bile acids and amino acid derivatives) that correlate with specific microbial genera, supporting integrated metabolic–microbiome relationships in depression pathophysiology (Hernández-Cacho et al., 2025; Liu et al., 2025). These sophisticated approaches not only help delineate causal and mechanistic pathways but also hold promise for informing more targeted microbiome-based therapies tailored to individual microbial–metabolite signatures.

Another major challenge is the considerable variability in the gut microbiota among individuals, which is influenced by genetics, diet, lifestyle, and environmental factors. This diversity limits the effectiveness of generalized interventions and highlights the need for personalized medicine approaches. Emerging technologies, such as microbiome sequencing and AI-driven analyses, could help identify microbial signatures associated with specific psychological disorders, leading to precision psychobiotics and customized dietary recommendations. However, the implementation of personalized microbiome-based therapies faces several hurdles, including high costs, accessibility issues, and the need for regulatory guidelines to ensure safety and efficacy. Despite these challenges, continued research and technological advancements hold the potential to revolutionize mental health care by integrating microbiome science into psychiatric treatment. As the field progresses, overcoming these obstacles will be crucial in unlocking the full therapeutic potential of microbiome-based interventions and developing more effective, individualized strategies for managing psychological disorders.

8 Linking global health and microbiome-driven mental health

Emerging evidence highlights that gut microbiota health is influenced not only by individual lifestyle choices but also by broader social, economic, and environmental factors. From a One Health perspective—which emphasizes the interdependence of human, animal, and environmental health—disruptions in local or global systems can significantly shape the gut microbiome composition and, consequently, mental health outcomes (Prescott et al., 2016; Maier and Al'Absi, 2017). In low-resource settings or areas affected by conflict, food insecurity and limited access to clean water are prevalent. These challenges, recognized within the United Nations Sustainable Development Goals (SDGs), are associated with malnutrition, exposure to environmental toxins, and increased antibiotic misuse, all of which contribute to gut dysbiosis.

Social inequality and political instability can restrict access to nutrient-rich diets and healthcare, further disrupting microbial balance and increasing vulnerability to stress-related mental health disorders. Additionally, environmental degradation, including loss of agricultural biodiversity and urban pollution, can alter microbial exposure during critical developmental windows, shaping the immune system and neurodevelopment in ways that may predispose individuals to psychological conditions (Singh et al., 2022). Addressing these systemic issues—through policies that promote food security, water sanitation, healthcare equity, and environmental protection—can support microbiome integrity and resilience, forming an upstream approach to mental health promotion on a global scale.

9 Summary

The complex relationship between the gut microbiome and the nervous system has emerged as a potential critical factor in fully understanding mental health and psychological disorders. The microbiome influences brain function through multiple pathways, including neural, immune, and metabolic mechanisms, with communication largely mediated by the vagus nerve, neurotransmitter modulation, and microbial metabolites such as SCFAs. Disruptions in microbial balance, or dysbiosis, have been linked to a range of psychiatric disorders, including depression, anxiety, schizophrenia, autism spectrum disorder, and bipolar disorder. Increasing evidence suggests that gut microbes contribute to neuroinflammation, immune dysregulation, and alterations in neurotransmitter production, all of which play key roles in the development and progression of mental health conditions.

With this growing body of evidence, microbiome-targeted therapies could offer promising new avenues for treatment. Probiotics, particularly psychobiotics, have demonstrated potential in regulating stress responses and improving mood by influencing the HPA axis and neurotransmitter pathways. FMT, although still used in psychiatry, has shown potential for restoring microbial diversity and decreasing symptoms in patients with neuropsychiatric conditions. Additionally, dietary interventions, including prebiotics and nutrient-rich foods, can support a healthy gut microbiome and contribute to mental well-being. However, despite these advancements, several challenges remain, particularly the need for large-scale clinical studies to confirm efficacy, the establishment of standardized treatment protocols, and a better understanding of the causal relationships between the microbiome and mental health. Personalized medicine approaches, leveraging microbiome sequencing and AI-driven analysis, may help tailor interventions to the individual’s microbiota, enhancing treatment effectiveness.

As research progresses, integrating microbiome science into psychiatric care could lead to a paradigm shift in mental health treatment. By addressing gut health as a key component of neurological and psychological well-being, future therapies may offer more effective, individualized, and holistic approaches to managing mental health disorders. However, overcoming current challenges—such as study limitations, variability in microbiota composition, and the need for regulatory frameworks—will be essential in translating these findings into practical, clinically viable solutions. The role of the microbiome in mental health remains an exciting and rapidly evolving field, with the potential to reshape our understanding of psychiatric disorders and open new doors for innovative treatments.

Author contributions

PA: Conceptualization, Writing – original draft. HK: Conceptualization, Writing – original draft. TB: Writing – review & editing. RT: Funding acquisition, Supervision, Writing – review & editing.

Funding

The author(s) declared that financial support was received for this work and/or its publication. Individual NSERC DG grants TB and to RT. RT grant supported graduate student HK and funded the OA fee.

Conflict of interest

The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Alameddine J., Godefroy E., Papargyris L., Sarrabayrouse G., Tabiasco J., Bridonneau C., et al. (2019). Faecalibacterium prausnitzii skews human DC to prime IL10-producing T cells through TLR2/6/JNK signaling and IL-10, IL-27, CD39, and IDO-1 induction. Front. Immunol. 10, 143. doi: 10.3389/fimmu.2019.00143

PubMed Abstract | Crossref Full Text | Google Scholar

Al-Ayadhi L., Zayed N., Bhat R. S., Moubayed N. M., Al-Muammar M. N., and El-Ansary A. (2021). The use of biomarkers associated with leaky gut as a diagnostic tool for early intervention in autism spectrum disorder: a systematic review. Gut Pathogens 13, 1–16. doi: 10.1186/s13099-021-00448-y

PubMed Abstract | Crossref Full Text | Google Scholar

Alotiby A. (2024). Immunology of stress: A review article. J. Clin. Med. 13, 6394. doi: 10.3390/jcm13216394

PubMed Abstract | Crossref Full Text | Google Scholar

An L., Wirth U., Koch D., Schirren M., Drefs M., Koliogiannis D., et al. (2022). The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases. J. Gastrointest. Surg. 26, 671–683. doi: 10.1007/s11605-021-05188-7

PubMed Abstract | Crossref Full Text | Google Scholar

Arneth B. M. (2018). Gut–brain axis biochemical signaling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function. Postgrad. Med. J. 94, 446–452. doi: 10.1136/postgradmedj-2017-135424

PubMed Abstract | Crossref Full Text | Google Scholar

Arslanova A., Tarasova A., Alexandrova A., Novoselova V., Shaidullov I., Khusnutdinova D., et al. (2021). Protective effects of probiotics on cognitive and motor functions, anxiety level, visceral sensitivity, oxidative stress and microbiota in mice with antibiotic-induced dysbiosis. Life 11, 764. doi: 10.3390/life11080764

PubMed Abstract | Crossref Full Text | Google Scholar

Averianova L. A., Balabanova L. A., Son O. M., Podvolotskaya A. B., and Tekutyeva L. A. (2020). Production of vitamin B2 (riboflavin) by microorganisms: an overview. Front. Bioeng. Biotechnol. 8, 570828. doi: 10.3389/fbioe.2020.570828

PubMed Abstract | Crossref Full Text | Google Scholar

Azhari A., Azizan F., and Esposito G. (2019). A systematic review of gut-immune-brain mechanisms in Autism Spectrum Disorder. Dev. Psychobiol. 61, 752–771. doi: 10.1002/dev.21803

PubMed Abstract | Crossref Full Text | Google Scholar

Bamicha V., Pergantis P., and Drigas A. (2024). The effect of gut microbiome, neurotransmitters, and digital insights in autism. Appl. Microbiol. 4, 1677–1701. doi: 10.3390/applmicrobiol4040114

Crossref Full Text | Google Scholar

Belizário J. E., Faintuch J., and Garay-Malpartida M. (2018). Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases. Mediators Inflamm. 2018, 2037838. doi: 10.1155/2018/2037838

PubMed Abstract | Crossref Full Text | Google Scholar

Bermúdez-Humarán L. G., Salinas E., Ortiz G. G., Ramirez-Jirano L. J., Morales J. A., and Bitzer-Quintero O. K. (2019). From probiotics to psychobiotics: live beneficial bacteria which act on the brain-gut axis. Nutrients 11, 890. doi: 10.3390/nu11040890

PubMed Abstract | Crossref Full Text | Google Scholar

Bertollo A. G., Santos C. F., Bagatini M. D., and Ignácio Z. M. (2025). Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Front. Neurosci. 19, 1541075. doi: 10.3389/fnins.2025.1541075

PubMed Abstract | Crossref Full Text | Google Scholar

Bhat A. N. (2021). Motor impairment increases in children with autism spectrum disorder as a function of social communication, cognitive and functional impairment, repetitive behavior severity, and comorbid diagnoses: A SPARK study report. Autism Res. 14, 202–219. doi: 10.1002/aur.2453

PubMed Abstract | Crossref Full Text | Google Scholar

Bhatia N. Y., Jalgaonkar M. P., Hargude A. B., Sherje A. P., Oza M. J., and Doshi G. M. (2023). Gut-brain axis and neurological disorders-how microbiomes affect our mental health. CNS Neurol. Disorders Drug Targets CNS Neurol. Disorders) 22, 1008–1030. doi: 10.2174/1871527321666220822172039

PubMed Abstract | Crossref Full Text | Google Scholar

Bianchetti G., De Maio F., Abeltino A., Serantoni C., Riente A., Santarelli G., et al. (2023). Unraveling the gut microbiome–diet connection: exploring the impact of digital precision and personalized nutrition on microbiota composition and host physiology. Nutrients 15, 3931. doi: 10.3390/nu15183931

PubMed Abstract | Crossref Full Text | Google Scholar

Bibi A., Zhang F., Shen J., Din A. U., and Xu Y. (2025). Behavioral alterations in antibiotic-treated mice associated with gut microbiota dysbiosis: insights from 16S rRNA and metabolomics. Front. Neurosci. 19, 1478304. doi: 10.3389/fnins.2025.1478304

PubMed Abstract | Crossref Full Text | Google Scholar

Birkeland E., Gharagozlian S., Birkeland K. I., Valeur J., Måge I., Rud I., et al. (2020). Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial. Eur. J. Nutr. 59, 3325–3338. doi: 10.1007/s00394-020-02282-5

PubMed Abstract | Crossref Full Text | Google Scholar

Borkent J., Ioannou M., Neijzen D., Haarman B. C., and Sommer I. E. (2025). Probiotic formulation for patients with bipolar or schizophrenia spectrum disorder: a double-blind, randomized placebo-controlled trial. Schizophr. Bull. 51 (6), 1568–1580. doi: 10.1093/schbul/sbae188

PubMed Abstract | Crossref Full Text | Google Scholar

Bornet F. R. and Brouns F. (2002). Immune-stimulating and gut health-promoting properties of short-chain fructo-oligosaccharides. Nutr. Rev. 60, 326–334. doi: 10.1301/002966402320583442

PubMed Abstract | Crossref Full Text | Google Scholar

Bosi A., Banfi D., Bistoletti M., Giaroni C., and Baj A. (2020). Tryptophan metabolites along the microbiota-gut-brain axis: an interkingdom communication system influencing the gut in health and disease. Int. J. Tryptophan Res. 13, 1178646920928984. doi: 10.1177/1178646920928984

PubMed Abstract | Crossref Full Text | Google Scholar

Businaro R. (2022). Food supplements to complement brain functioning. The benefits of a combination of magnesium, folic acid, omega-3 fatty acids and vitamin E. F1000Research 11, 1–18. doi: 10.12688/f1000research.75856.1

Crossref Full Text | Google Scholar

Busse M., Busse S., Myint A. M., Gos T., Dobrowolny H., Müller U. J., et al. (2015). Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? Eur. Arch. Psychiatry Clin. Neurosci. 265, 321–329. doi: 10.1007/s00406-014-0562-0

PubMed Abstract | Crossref Full Text | Google Scholar

Calderón-Guzmán D., Hernández-Islas J. L., Espitia-Vázquez I., Barragán-Mejía G., Hernández-García E., Santamaría-del Ángel D., et al. (2004). Pyridoxine, regardless of serotonin levels, increases production of 5-hydroxytryptophan in rat brain. Arch. Med. Res. 35, 271–274. doi: 10.1016/j.arcmed.2004.03.003

PubMed Abstract | Crossref Full Text | Google Scholar

Candelli M., Franza L., Pignataro G., Ojetti V., Covino M., Piccioni A., et al. (2021). Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases. Int. J. Mol. Sci. 22, 6242. doi: 10.3390/ijms22126242

PubMed Abstract | Crossref Full Text | Google Scholar

Carlessi A. S., Borba L. A., Zugno A. I., Quevedo J., and Réus G. Z. (2021). Gut microbiota–brain axis in depression: The role of neuroinflammation. Eur. J. Neurosci. 53, 222–235. doi: 10.1111/ejn.14631

PubMed Abstract | Crossref Full Text | Google Scholar

Chancharoenthana W., Kamolratanakul S., Schultz M. J., and Leelahavanichkul A. (2023). The leaky gut and the gut microbiome in sepsis–targets in research and treatment. Clin. Sci. 137, 645–662. doi: 10.1042/CS20220777

PubMed Abstract | Crossref Full Text | Google Scholar

Chand T. and Savitri B. (2016). “Vitamin B3, niacin,” in Industrial biotechnology of vitamins, biopigments, and antioxidants. eds. Vandamme E. J. and Revuelta J. L. (Weinheim, Germany: Wiley-VHC, Weinheim) 41–65. doi: 10.1002/9783527681754.ch3

Crossref Full Text | Google Scholar

Chelakkot C., Ghim J., and Ryu S. H. (2018). Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp. Mol. Med. 50, 1–9. doi: 10.1038/s12276-018-0126-x

PubMed Abstract | Crossref Full Text | Google Scholar

Chen X., Shi S., Sun C., and Li S. (2024). A study of the relationship between inflammatory immune function and intestinal Flora in adolescent patients with first-episode depression. Actas Españolas Psiquiatría. 52, 1.

PubMed Abstract | Google Scholar

Chinna Meyyappan A., Forth E., Wallace C. J., and Milev R. (2020). Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review. BMC Psychiatry 20, 299. doi: 10.21203/rs.3.rs-16542/v1

PubMed Abstract | Crossref Full Text | Google Scholar

Cho N. A. (2021). Impact of Alterations to Early Life Microbiota (Antibiotics, Prebiotics, and C-Section) on Body Weight and Brain Development (PhD thesis). (Canada: University of Calgary).

Google Scholar

Cicero A. and Minervino A. (2022). Combined action of SAMe, Folate, and Vitamin B12 in the treatment of mood disorders: a review. Eur. Rev. Med. Pharmacol. Sci. 26, 2443–2459. doi: 10.26355/eurrev_202204_28479

PubMed Abstract | Crossref Full Text | Google Scholar

Conn K. A., Borsom E. M., and Cope E. K. (2024). Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease. Gut Microbes 16, 2371950. doi: 10.1080/19490976.2024.2371950

PubMed Abstract | Crossref Full Text | Google Scholar

Corano Scheri G., Fard S. N., Schietroma I., Mastrangelo A., Pinacchio C., Giustini N., et al. (2017). Modulation of tryptophan/serotonin pathway by probiotic supplementation in human immunodeficiency virus–positive patients: preliminary results of a new study approach. Int. J. Tryptophan Res. 10, 1178646917710668. doi: 10.1177/1178646917710668

PubMed Abstract | Crossref Full Text | Google Scholar

Correia A. S. and Vale N. (2022). Tryptophan metabolism in depression: a narrative review with a focus on serotonin and kynurenine pathways. Int. J. Mol. Sci. 23, 8493. doi: 10.3390/ijms23158493

PubMed Abstract | Crossref Full Text | Google Scholar

Cryan J. F., O'Riordan K. J., Cowan C. S., Sandhu K. V., Bastiaanssen T. F., Boehme M., et al. (2019). The microbiota-gut-brain axis. Physiol. Rev. doi: 10.1152/physrev.00018.2018

PubMed Abstract | Crossref Full Text | Google Scholar

Dahiya D. and Nigam P. S. (2023). Antibiotic-therapy-induced gut dysbiosis affecting gut microbiota—brain axis and cognition: restoration by intake of probiotics and synbiotics. Int. J. Mol. Sci. 24, 3074. doi: 10.3390/ijms24043074

PubMed Abstract | Crossref Full Text | Google Scholar

David L. A., Maurice C. F., Carmody R. N., Gootenberg D. B., Button J. E., Wolfe B. E., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563. doi: 10.1038/nature12820

PubMed Abstract | Crossref Full Text | Google Scholar

Dedovic K., Duchesne A., Andrews J., Engert V., and Pruessner J. C. (2009). The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. Neuroimage 47, 864–871. doi: 10.1016/j.neuroimage.2009.05.074

PubMed Abstract | Crossref Full Text | Google Scholar

Deng W., Yi P., Xiong Y., Ying J., Lin Y., Dong Y., et al. (2024). Gut metabolites acting on the gut-brain Axis: regulating the functional state of microglia. Aging Dis. 15, 480. doi: 10.14336/AD.2023.0727

PubMed Abstract | Crossref Full Text | Google Scholar

Dinan T. G. and Cryan J. F. (2017). The microbiome-gut-brain axis in health and disease. Gastroenterol. Clin. 46, 77–89. doi: 10.1016/j.gtc.2016.09.007

PubMed Abstract | Crossref Full Text | Google Scholar

Doney E., Cadoret A., Dion-Albert L., Lebel M., and Menard C. (2022). Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders. Eur. J. Neurosci. 55, 2851–2894. doi: 10.1111/ejn.15239

PubMed Abstract | Crossref Full Text | Google Scholar

Du Y., Gao X.-R., Peng L., and Ge J.-F. (2020). Crosstalk between the microbiota-gut-brain axis and depression. Heliyon 6. doi: 10.1016/j.heliyon.2020.e04097

PubMed Abstract | Crossref Full Text | Google Scholar

Eicher T. P. and Mohajeri M. H. (2022). Overlapping mechanisms of action of brain-active bacteria and bacterial metabolites in the pathogenesis of common brain diseases. Nutrients 14, 2661. doi: 10.3390/nu14132661

PubMed Abstract | Crossref Full Text | Google Scholar

Elgellaie A., Thomas S. J., Kaelle J., Bartschi J., and Larkin T. (2023). Pro-inflammatory cytokines IL-1α, IL-6 and TNF-α in major depressive disorder: Sex-specific associations with psychological symptoms. Eur. J. Neurosci. 57, 1913–1928. doi: 10.1111/ejn.15992

PubMed Abstract | Crossref Full Text | Google Scholar

Ellis J. L., Karl J. P., Oliverio A. M., Fu X., Soares J. W., Wolfe B. E., et al. (2021). Dietary vitamin K is remodeled by gut microbiota and influences community composition. Gut Microbes 13, 1887721. doi: 10.1080/19490976.2021.1887721

PubMed Abstract | Crossref Full Text | Google Scholar

Eshraghi R. S., Davies C., Iyengar R., Perez L., Mittal R., and Eshraghi A. A. (2020). Gut-induced inflammation during development may compromise the blood-brain barrier and predispose to autism spectrum disorder. J. Clin. Med. 10, 27. doi: 10.3390/jcm10010027

PubMed Abstract | Crossref Full Text | Google Scholar

Fassarella M., Blaak E. E., Penders J., Nauta A., Smidt H., and Zoetendal E. G. (2021). Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health. Gut 70, 595–605. doi: 10.1136/gutjnl-2020-321747

PubMed Abstract | Crossref Full Text | Google Scholar

Fattorusso A., Di Genova L., Dell’Isola G. B., Mencaroni E., and Esposito S. (2019). Autism spectrum disorders and the gut microbiota. Nutrients 11, 521. doi: 10.3390/nu11030521

PubMed Abstract | Crossref Full Text | Google Scholar

Fock E. and Parnova R. (2023). Mechanisms of blood–brain barrier protection by microbiota-derived short-chain fatty acids. Cells 12, 657. doi: 10.3390/cells12040657

PubMed Abstract | Crossref Full Text | Google Scholar

Foster J. A., Rinaman L., and Cryan J. F. (2017). Stress & the gut-brain axis: regulation by the microbiome. Neurobiol. Stress 7, 124–136. doi: 10.1016/j.ynstr.2017.03.001

PubMed Abstract | Crossref Full Text | Google Scholar

Fox M., Lee S. M., Wiley K. S., Lagishetty V., Sandman C. A., Jacobs J. P., et al. (2022). Development of the infant gut microbiome predicts temperament across the first year of life. Dev. Psychopathol. 34, 1914–1925. doi: 10.1017/S0954579421000456

PubMed Abstract | Crossref Full Text | Google Scholar

Gao J., Xu K., Liu H., Liu G., Bai M., Peng C., et al. (2018). Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front. Cell. Infect. Microbiol. 8, 13. doi: 10.3389/fcimb.2018.00013

PubMed Abstract | Crossref Full Text | Google Scholar

Garcia-Gutierrez E., Narbad A., and Rodríguez J. M. (2020). Autism spectrum disorder associated with gut microbiota at immune, metabolomic, and neuroactive level. Front. Neurosci. 14, 578666. doi: 10.3389/fnins.2020.578666

PubMed Abstract | Crossref Full Text | Google Scholar

Garzone S., Charitos I. A., Mandorino M., Maggiore M. E., Capozzi L., Cakani B., et al. (2025). Can we modulate our second brain and its metabolites to change our mood? A systematic review on efficacy, mechanisms, and future directions of “Psychobiotics. Int. J. Mol. Sci. 26, 1972. doi: 10.3390/ijms26051972

PubMed Abstract | Crossref Full Text | Google Scholar

Ghosh T. S., Rampelli S., Jeffery I. B., Santoro A., Neto M., Capri M., et al. (2020). Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut 69, 1218–1228. doi: 10.1136/gutjnl-2019-319654

PubMed Abstract | Crossref Full Text | Google Scholar

Gibson G. E., Hirsch J. A., Fonzetti P., Jordan B. D., Cirio R. T., and Elder J. (2016). Vitamin B1 (thiamine) and dementia. Ann. New York Acad. Sci. 1367, 21–30. doi: 10.1111/nyas.13031

PubMed Abstract | Crossref Full Text | Google Scholar

Gokulakrishnan K., Nikhil J., Viswanath B., Thirumoorthy C., Narasimhan S., Devarajan B., et al. (2023). Comparison of gut microbiome profile in patients with schizophrenia and healthy controls-A plausible non-invasive biomarker? J. Psychiatr. Res. 162, 140–149. doi: 10.1016/j.jpsychires.2023.05.021

PubMed Abstract | Crossref Full Text | Google Scholar

González-Arancibia C., Urrutia-Piñones J., Illanes-González J., Martinez-Pinto J., Sotomayor-Zárate R., Julio-Pieper M., et al. (2019). Do your gut microbes affect your brain dopamine? Psychopharmacology 236, 1611–1622. doi: 10.1007/s00213-019-05265-5

PubMed Abstract | Crossref Full Text | Google Scholar

Grajek M., Krupa-Kotara K., Białek-Dratwa A., Sobczyk K., Grot M., Kowalski O., et al. (2022). Nutrition and mental health: A review of current knowledge about the impact of diet on mental health. Front. Nutr. 9, 943998. doi: 10.3389/fnut.2022.943998

PubMed Abstract | Crossref Full Text | Google Scholar

Green J. E., Wrobel A., Todd E., Marx W., Berk M., Lotfaliany M., et al. (2025). Early antibiotic exposure and risk of psychiatric and neurocognitive outcomes: systematic review and meta-analysis. Br. J. Psychiatry 226(3), 171–183. doi: 10.1192/bjp.2024.121

PubMed Abstract | Crossref Full Text | Google Scholar

Guida F., Turco F., Iannotta M., De Gregorio D., Palumbo I., Sarnelli G., et al. (2018). Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav. Immun. 67, 230–245. doi: 10.1016/j.bbi.2017.09.001

PubMed Abstract | Crossref Full Text | Google Scholar

Guo J., Sun X., Yuan Y., Chen Q., Ou Z., Deng Z., et al. (2023). Metabolic engineering of Saccharomyces cerevisiae for vitamin B5 production. J. Agric. Food Chem. 71, 7408–7417. doi: 10.1021/acs.jafc.3c01082

PubMed Abstract | Crossref Full Text | Google Scholar

Han S.-K. and Kim D. H. (2019). Lactobacillus mucosae and Bifidobacterium longum synergistically alleviate immobilization stress-induced anxiety/depression in mice by suppressing gut dysbiosis. J. Microbiol. Biotechnol. 29, 1369–1374. doi: 10.4014/jmb.1907.07044

PubMed Abstract | Crossref Full Text | Google Scholar

Hassamal S. (2023). Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Front. Psychiatry 14, 1130989. doi: 10.3389/fpsyt.2023.1130989

PubMed Abstract | Crossref Full Text | Google Scholar

He Q., Wang W., Xu D., Xiong Y., Tao C., You C., et al. (2024). Potential causal association between gut microbiome and posttraumatic stress disorder. Trans. Psychiatry 14, 67. doi: 10.1038/s41398-024-02765-7

PubMed Abstract | Crossref Full Text | Google Scholar

Hernández-Cacho A., García-Gavilán J. F., Atzeni A., Konstanti P., Belzer C., Vioque J., et al. (2025). Multi-omics approach identifies gut microbiota variations associated with depression. NPJ Biofilms Microb. 11, 1–12. doi: 10.1038/s41522-025-00707-9

PubMed Abstract | Crossref Full Text | Google Scholar

Hirota T. and King B. H. (2023). Autism spectrum disorder: a review. Jama 329, 157–168. doi: 10.1001/jama.2022.23661

PubMed Abstract | Crossref Full Text | Google Scholar

Huang X., Hussain B., and Chang J. (2021). Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. CNS Neurosci. Ther. 27, 36–47. doi: 10.1111/cns.13569

PubMed Abstract | Crossref Full Text | Google Scholar

Jacka F. N., O’Neil A., Opie R., Itsiopoulos C., Cotton S., Mohebbi M., et al. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’trial). BMC Med. 15, 23. doi: 10.1186/s12916-017-0791-y

PubMed Abstract | Crossref Full Text | Google Scholar

Jang H.-M., Lee K.-E., and Kim D.-H. (2019). The preventive and curative effects of Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 on immobilization stress-induced anxiety/depression and colitis in mice. Nutrients 11, 819. doi: 10.3390/nu11040819

PubMed Abstract | Crossref Full Text | Google Scholar

Januszewski J., Forma A., Kłodnicka K., Brachet A., and Baj J. (2024). Microbiological bases of obsessive−compulsive disorder–the role of viruses, bacteria, and parasites in the onset and progression of OCD. Acta Neurobiol. Experimentalis 84, 230–242. doi: 10.55782/ane-2024-2516

PubMed Abstract | Crossref Full Text | Google Scholar

Jarosz Ł. S., Socała K., Michalak K., Wiater A., Ciszewski A., Majewska M., et al. (2024). The effect of psychoactive bacteria, Bifidobacterium longum Rosell®-175 and Lactobacillus rhamnosus JB-1, on brain proteome profiles in mice. Psychopharmacology 241, 925–945. doi: 10.1007/s00213-023-06519-z

PubMed Abstract | Crossref Full Text | Google Scholar

Jehn C., Becker B., Flath B., Nogai H., Vuong L., Schmid P., et al. (2015). Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. J. Neuroimmunol. 287, 88–92. doi: 10.1016/j.jneuroim.2015.08.012

PubMed Abstract | Crossref Full Text | Google Scholar

Jeong J., Lee Y., Yoon S., Kim J.-H., and Kim W. (2021). Lactiplantibacillus plantarum LRCC5314 includes a gene for serotonin biosynthesis via the tryptophan metabolic pathway. J. Microbiol. 59, 1092–1103. doi: 10.1007/s12275-021-1472-2

PubMed Abstract | Crossref Full Text | Google Scholar

Kakee A., Takanaga H., Terasaki T., Naito M., Tsuruo T., and Sugiyama Y. (2001). Efflux of a suppressive neurotransmitter, GABA, across the blood–brain barrier. J. Neurochem. 79, 110–118. doi: 10.1046/j.1471-4159.2001.00540.x

PubMed Abstract | Crossref Full Text | Google Scholar

Karemaker J. M. (2022). The multibranched nerve: vagal function beyond heart rate variability. Biol. Psychol. 172, 108378. doi: 10.1016/j.biopsycho.2022.108378

PubMed Abstract | Crossref Full Text | Google Scholar

Kato-Kataoka A., Nishida K., Takada M., Kawai M., Kikuchi-Hayakawa H., Suda K., et al. (2016). Fermented milk containing Lactobacillus casei strain Shirota preserves the diversity of the gut microbiota and relieves abdominal dysfunction in healthy medical students exposed to academic stress. Appl. Environ. Microbiol. 82, 3649–3658. doi: 10.1128/AEM.04134-15

PubMed Abstract | Crossref Full Text | Google Scholar

Kelly J. R., Kennedy P. J., Cryan J. F., Dinan T. G., Clarke G., and Hyland N. P. (2015). Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci. 9, 392. doi: 10.3389/fncel.2015.00392

PubMed Abstract | Crossref Full Text | Google Scholar

Kelly J. R., Minuto C., Cryan J. F., Clarke G., and Dinan T. G. (2021). The role of the gut microbiome in the development of schizophrenia. Schizophr. Res. 234, 4–23. doi: 10.1016/j.schres.2020.02.010

PubMed Abstract | Crossref Full Text | Google Scholar

Keszthelyi D., Troost F., and Masclee A. (2009). Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function. Neurogastroenterol. Motility 21, 1239–1249. doi: 10.1111/j.1365-2982.2009.01370.x

PubMed Abstract | Crossref Full Text | Google Scholar

Khan M. F., Khodve G., Yadav S., Mallick K., and Banerjee S. (2025). Probiotic treatment improves post-traumatic stress disorder outcomes in mice. Behav. Brain Res. 476, 115246. doi: 10.1016/j.bbr.2024.115246

PubMed Abstract | Crossref Full Text | Google Scholar

Kim C.-S., Jung S., Hwang G.-S., and Shin D.-M. (2023). Gut microbiota indole-3-propionic acid mediates neuroprotective effect of probiotic consumption in healthy elderly: A randomized, double-blind, placebo-controlled, multicenter trial and in vitro study. Clin. Nutr. 42, 1025–1033. doi: 10.1016/j.clnu.2023.04.001

PubMed Abstract | Crossref Full Text | Google Scholar

Kochalska K., Oakden W., Słowik T., Chudzik A., Pankowska A., Łazorczyk A., et al. (2020). Dietary supplementation with Lactobacillus rhamnosus JB-1 restores brain neurochemical balance and mitigates the progression of mood disorder in a rat model of chronic unpredictable mild stress. Nutr. Res. 82, 44–57. doi: 10.1016/j.nutres.2020.06.019

PubMed Abstract | Crossref Full Text | Google Scholar

Kong J., Fang J., Park J., Li S., and Rong P. (2018). Treating depression with transcutaneous auricular vagus nerve stimulation: state of the art and future perspectives. Front. Psychiatry 9, 20. doi: 10.3389/fpsyt.2018.00020

PubMed Abstract | Crossref Full Text | Google Scholar

Konopelski P. and Mogilnicka I. (2022). Biological effects of indole-3-propionic acid, a gut microbiota-derived metabolite, and its precursor tryptophan in mammals’ health and disease. Int. J. Mol. Sci. 23, 1222. doi: 10.3390/ijms23031222

PubMed Abstract | Crossref Full Text | Google Scholar

Kowalski K., Szponar B., Bochen P., Żebrowska-Różańska P., Łaczmański Ł., Samochowiec J., et al. (2023). Altered levels of fecal short-chain fatty acids are associated with subclinical inflammation and worse cognitive performance in patients with schizophrenia. J. Psychiatr. Res. 165, 298–304. doi: 10.1016/j.jpsychires.2023.07.042

PubMed Abstract | Crossref Full Text | Google Scholar

Lavebratt C., Yang L. L., Giacobini M., Forsell Y., Schalling M., Partonen T., et al. (2019). Early exposure to antibiotic drugs and risk for psychiatric disorders: a population-based study. Trans. Psychiatry 9, 317. doi: 10.1038/s41398-019-0653-9

PubMed Abstract | Crossref Full Text | Google Scholar

Leclercq S., Forsythe P., and Bienenstock J. (2016). Posttraumatic stress disorder: does the gut microbiome hold the key? Can. J. Psychiatry 61, 204–213. doi: 10.1177/0706743716635535

PubMed Abstract | Crossref Full Text | Google Scholar

Lee J.-Y., Tsolis R. M., and Bäumler A. J. (2022). The microbiome and gut homeostasis. Science 377, eabp9960. doi: 10.1126/science.abp9960

PubMed Abstract | Crossref Full Text | Google Scholar

Leo E. E. M. and Campos M. R. S. (2020). Effect of ultra-processed diet on gut microbiota and thus its role in neurodegenerative diseases. Nutrition 71, 110609. doi: 10.1016/j.nut.2019.110609

PubMed Abstract | Crossref Full Text | Google Scholar

Levite M. (2016). Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol. 216, 42–89. doi: 10.1111/apha.12476

PubMed Abstract | Crossref Full Text | Google Scholar

Levy M., Kolodziejczyk A. A., Thaiss C. A., and Elinav E. (2017). Dysbiosis and the immune system. Nat. Rev. Immunol. 17, 219–232. doi: 10.1038/nri.2017.7

PubMed Abstract | Crossref Full Text | Google Scholar

Li G., Dong S., Liu C., Yang J., Rensen P. C., and Wang Y. (2025). Serotonin signaling to regulate energy metabolism: a gut microbiota perspective. Life Metab. 4, loae039. doi: 10.1093/lifemeta/loae039

PubMed Abstract | Crossref Full Text | Google Scholar

Li Z., Lai J., Zhang P., Ding J., Jiang J., Liu C., et al. (2022). Multi-omics analyses of serum metabolome, gut microbiome and brain function reveal dysregulated microbiota-gut-brain axis in bipolar depression. Mol. Psychiatry 27, 4123–4135. doi: 10.1038/s41380-022-01569-9

PubMed Abstract | Crossref Full Text | Google Scholar

Li N., Wang Q., Wang Y., Sun A., Lin Y., Jin Y., et al. (2019). Fecal microbiota transplantation from chronic unpredictable mild stress mice donors affects anxiety-like and depression-like behavior in recipient mice via the gut microbiota-inflammation-brain axis. Stress 22, 592–602. doi: 10.1080/10253890.2019.1617267

PubMed Abstract | Crossref Full Text | Google Scholar

Liang S., Wu X., Hu X., Wang T., and Jin F. (2018). Recognizing depression from the microbiota–gut–brain axis. Int. J. Mol. Sci. 19, 1592. doi: 10.3390/ijms19061592

PubMed Abstract | Crossref Full Text | Google Scholar

Linares D., Fitzgerald G., Hill C., Stanton C., and Ross P. (2017). Production of vitamins, exopolysaccharides and bacteriocins by probiotic bacteria. Probiotic Dairy Prod., 359–388. doi: 10.1002/9781119214137.ch9

Crossref Full Text | Google Scholar

Lipski E. (2020). “The GUT-immune system,” in Integrative and Functional Medical Nutrition Therapy: Principles and Practices, (Cham, Switzerland: Humana press Springer International Publishing), 367–377.

Google Scholar

Liu Y. and Forsythe P. (2021). Vagotomy and insights into the microbiota-gut-brain axis. Neurosci. Res. 168, 20–27. doi: 10.1016/j.neures.2021.04.001

PubMed Abstract | Crossref Full Text | Google Scholar

Liu S., Li Y., Shi Y., Rao Z., Zhang Y., Zhang Y., et al. (2025). Multi-omics analyses of the gut microbiome, fecal metabolome, and multimodal brain MRI reveal the role of Alistipes and its related metabolites in major depressive disorder. psychol. Med. 55, e190. doi: 10.1017/S003329172510072X

PubMed Abstract | Crossref Full Text | Google Scholar

Liu J., Tan Y., Cheng H., Zhang D., Feng W., and Peng C. (2022). Functions of gut microbiota metabolites, current status and future perspectives. Aging Dis 13, 1106. doi: 10.14336/AD.2022.0104

PubMed Abstract | Crossref Full Text | Google Scholar

Liu L. and Zhu G. (2018). Gut–brain axis and mood disorder. Front. Psychiatry 9, 223. doi: 10.3389/fpsyt.2018.00223

PubMed Abstract | Crossref Full Text | Google Scholar

Luczynski P., McVey Neufeld K.-A., Oriach C. S., Clarke G., Dinan T. G., and Cryan J. F. (2016). Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. Int. J. Neuropsychopharmacol. 19, pyw020. doi: 10.1093/ijnp/pyw020

PubMed Abstract | Crossref Full Text | Google Scholar

Lukić I., Ivković S., Mitić M., and Adžić M. (2022). Tryptophan metabolites in depression: modulation by gut microbiota. Front. Behav. Neurosci. 16, 987697. doi: 10.3389/fnbeh.2022.987697

PubMed Abstract | Crossref Full Text | Google Scholar

Ma J. and Song X.-Q. (2023). Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia. World J. Psychiatry 13, 724. doi: 10.5498/wjp.v13.i10.724

PubMed Abstract | Crossref Full Text | Google Scholar

MacKay M., Yang B. H., Dursun S. M., and Baker G. B. (2024). The gut-brain axis and the microbiome in anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder. Curr. Neuropharmacol. 22, 866–883. doi: 10.2174/1570159X21666230222092029

PubMed Abstract | Crossref Full Text | Google Scholar

Maier K. J. and Al'Absi M. (2017). Toward a biopsychosocial ecology of the human microbiome, brain-gut axis, and health. Psychosom. Med. 79, 947–957. doi: 10.1097/PSY.0000000000000515

PubMed Abstract | Crossref Full Text | Google Scholar

Manchia M., Squassina A., Pisanu C., Congiu D., Garzilli M., Guiso B., et al. (2019). Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. Int. J. Bipolar Disord. 7, 1–7. doi: 10.1186/s40345-019-0163-y

PubMed Abstract | Crossref Full Text | Google Scholar

Mayer E. A., Nance K., and Chen S. (2022). The gut–brain axis. Annu. Rev. Med. 73, 439–453. doi: 10.1146/annurev-med-042320-014032

PubMed Abstract | Crossref Full Text | Google Scholar

McCutcheon R. A., Keefe R. S., and McGuire P. K. (2023). Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol. Psychiatry 28, 1902–1918. doi: 10.1038/s41380-023-01949-9

PubMed Abstract | Crossref Full Text | Google Scholar

McIntyre R. S., Berk M., Brietzke E., Goldstein B. I., López-Jaramillo C., Kessing L. V., et al. (2020). Bipolar disorders. Lancet 396, 1841–1856. doi: 10.1016/S0140-6736(20)31544-0

PubMed Abstract | Crossref Full Text | Google Scholar

Meher A. K., Acharya B., and Sahu P. K. (2024). Probiotics: Bridging the interplay of a healthy gut and psychoneurological well-being. Food Bioeng. 3, 126–147. doi: 10.1002/fbe2.12081

Crossref Full Text | Google Scholar

Meng X., Zhang G., Cao H., Yu D., Fang X., de Vos W. M., et al. (2020). Gut dysbacteriosis and intestinal disease: mechanism and treatment. J. Appl. Microbiol. 129, 787–805. doi: 10.1111/jam.14661

PubMed Abstract | Crossref Full Text | Google Scholar

Merlo G., Bachtel G., and Sugden S. G. (2024). Gut microbiota, nutrition, and mental health. Front. Nutr. 11, 1337889. doi: 10.3389/fnut.2024.1337889

PubMed Abstract | Crossref Full Text | Google Scholar

Michlewska S., Dransfield I., Megson I. L., and Rossi A. G. (2009). Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-α. FASEB J. 23, 844–54. doi: 10.1096/fj.08-121228

PubMed Abstract | Crossref Full Text | Google Scholar

Minvielle M. J., Eguren K., and Melander C. (2013). Highly active modulators of indole signaling alter pathogenic behaviours in gram-negative and gram-positive bacteria. Chem. A Eur. J. 19, 17595–17602. doi: 10.1002/chem.201303510

PubMed Abstract | Crossref Full Text | Google Scholar

Mishra S. P., Karunakar P., Taraphder S., and Yadav H. (2020). Free fatty acid receptors 2 and 3 as microbial metabolite sensors to shape host health: pharmacophysiological view. Biomedicines 8, 154. doi: 10.3390/biomedicines8060154

PubMed Abstract | Crossref Full Text | Google Scholar

Mitrea L., Nemeş S.-A., Szabo K., Teleky B.-E., and Vodnar D.-C. (2022). Guts imbalance imbalances the brain: a review of gut microbiota association with neurological and psychiatric disorders. Front. Med. 9, 813204. doi: 10.3389/fmed.2022.813204

PubMed Abstract | Crossref Full Text | Google Scholar

Mittal R., Debs L. H., Patel A. P., Nguyen D., Patel K., O'Connor G., et al. (2017). Neurotransmitters: The critical modulators regulating gut–brain axis. J. Cell. Physiol. 232, 2359–2372. doi: 10.1002/jcp.25518

PubMed Abstract | Crossref Full Text | Google Scholar

Mohajeri M. H., Brummer R. J., Rastall R. A., Weersma R. K., Harmsen H. J., Faas M., et al. (2018). The role of the microbiome for human health: from basic science to clinical applications. Eur. J. Nutr. 57, 1–14. doi: 10.1007/s00394-018-1703-4

PubMed Abstract | Crossref Full Text | Google Scholar

Mu X., Feng L., Wang Q., Li H., Zhou H., Yi W., et al. (2025). Decreased gut microbiome-derived indole-3-propionic acid mediates the exacerbation of myocardial ischemia/reperfusion injury following depression via the brain-gut-heart axis. Redox Biol. 81, 103580. doi: 10.1016/j.redox.2025.103580

PubMed Abstract | Crossref Full Text | Google Scholar

Mundula T., Russo E., Curini L., Giudici F., Piccioni A., Franceschi F., et al. (2022). Chronic systemic low-grade inflammation and modern lifestyle: The dark role of gut microbiota on related diseases with a focus on COVID-19 pandemic. Curr. Med. Chem. 29, 5370–5396. doi: 10.2174/0929867329666220430131018

PubMed Abstract | Crossref Full Text | Google Scholar

Muneer A. (2020). Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations. Clin. Psychopharmacol. Neurosci. 18, 507. doi: 10.9758/cpn.2020.18.4.507

PubMed Abstract | Crossref Full Text | Google Scholar

Nara S., Parasher G., Malhotra B. D., and Rawat M. (2023). Novel role of folate (vitamin B9) released by fermenting bacteria under Human Intestine like environment. Sci. Rep. 13, 20226. doi: 10.1038/s41598-023-47243-0

PubMed Abstract | Crossref Full Text | Google Scholar

Needham B. D., Funabashi M., Adame M. D., Wang Z., Boktor J. C., Haney J., et al. (2022). A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature 602, 647–653. doi: 10.1038/s41586-022-04396-8

PubMed Abstract | Crossref Full Text | Google Scholar

Nie D., Wang D., Wang Z., Fang Q., Wang H., Xie W., et al. (2024). The gut microbiome in patients with Cushing’s disease affects depression-and anxiety-like behavior in mice. Microbiome 12, 225. doi: 10.1186/s40168-024-01939-1

PubMed Abstract | Crossref Full Text | Google Scholar

Niehues M. and Hensel A. (2009). In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J. Pharm. Pharmacol. 61, 1303–1307. doi: 10.1211/jpp.61.10.0005

PubMed Abstract | Crossref Full Text | Google Scholar

Nikolova V. L., Smith M. R., Hall L. J., Cleare A. J., Stone J. M., and Young A. H. (2021). Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis. JAMA Psychiatry 78, 1343–1354. doi: 10.1001/jamapsychiatry.2021.2573

PubMed Abstract | Crossref Full Text | Google Scholar

Nogal A., Valdes A. M., and Menni C. (2021). The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes 13, 1897212. doi: 10.1080/19490976.2021.1897212

PubMed Abstract | Crossref Full Text | Google Scholar

O'Riordan K. J., Collins M. K., Moloney G. M., Knox E. G., Aburto M. R., Fülling C., et al. (2022). Short chain fatty acids: Microbial metabolites for gut-brain axis signaling. Mol. Cell. Endocrinol. 546, 111572. doi: 10.1016/j.mce.2022.111572

PubMed Abstract | Crossref Full Text | Google Scholar

Oleskin A., Sorokina E., and Shilovsky G. (2021). Interaction of catecholamines with microorganisms, neurons, and immune cells. Biol. Bull. Rev. 11, 358–367. doi: 10.1134/S2079086421040058

Crossref Full Text | Google Scholar

Öztürk M., Yalın Sapmaz Ş., Kandemir H., Taneli F., and Aydemir Ö. (2021). The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. Int. J. Clin. Pract. 75, e13739. doi: 10.1111/ijcp.13739

PubMed Abstract | Crossref Full Text | Google Scholar

Parada Venegas D., de la Fuente M. K., Landskron G., González M. J., Quera R., Dijkstra G., et al. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 277. doi: 10.3389/fimmu.2019.00277

PubMed Abstract | Crossref Full Text | Google Scholar

Parker B. J., Wearsch P. A., Veloo A. C., and Rodriguez-Palacios A. (2020). The genus Alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front. Immunol. 11, 906. doi: 10.3389/fimmu.2020.00906

PubMed Abstract | Crossref Full Text | Google Scholar

Patel V. (2021). “The gut microbiome,” in A prescription for healthy living: A guide to lifestyle medicine, ed. Short E. (London UK: The Academic Press), 165–175. doi: 10.1016/B978-0-12-821573-9.00015-1

Crossref Full Text | Google Scholar

Peng H., Ouyang L., Li D., Li Z., Yuan L., Fan L., et al. (2022). Short-chain fatty acids in patients with schizophrenia and ultra-high risk population. Front. Psychiatry 13, 977538. doi: 10.3389/fpsyt.2022.977538

PubMed Abstract | Crossref Full Text | Google Scholar

Perdijk O., Azzoni R., and Marsland B. J. (2024). The microbiome: an integral player in immune homeostasis and inflammation in the respiratory tract. Physiol. Rev. 104, 835–879. doi: 10.1152/physrev.00020.2023

PubMed Abstract | Crossref Full Text | Google Scholar

Petakh P., Duve K., Oksenych V., Behzadi P., and Kamyshnyi O. (2024). Molecular mechanisms and therapeutic possibilities of short-chain fatty acids in posttraumatic stress disorder patients: a mini-review. Front. Neurosci. 18, 1394953. doi: 10.3389/fnins.2024.1394953

PubMed Abstract | Crossref Full Text | Google Scholar

Pirbaglou M., Katz J., de Souza R. J., Stearns J. C., Motamed M., and Ritvo P. (2016). Probiotic supplementation can positively affect anxiety and depressive symptoms: a systematic review of randomized controlled trials. Nutr. Res. 36, 889–898. doi: 10.1016/j.nutres.2016.06.009

PubMed Abstract | Crossref Full Text | Google Scholar

Powers H. J. (2003). Riboflavin (vitamin B-2) and health. Am. J. Clin. Nutr. 77, 1352–1360. doi: 10.1093/ajcn/77.6.1352

PubMed Abstract | Crossref Full Text | Google Scholar

Prescott S. L., Millstein R. A., Katzman M. A., and Logan A. C. (2016). Biodiversity, the human microbiome and mental health: moving toward a new clinical ecology for the 21st century? Int. J. Biodivers. 2016, 2718275. doi: 10.1155/2016/2718275

Crossref Full Text | Google Scholar

Prousky J. (2010). Vitamin B3 for depression: case report and review of the literature. J. Orthomol. Med. 25, 137–147

Google Scholar

Qin L., Wu X., Block M. L., Liu Y., Breese G. R., Hong J. S., et al. (2007). Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55, 453–462. doi: 10.1002/glia.20467

PubMed Abstract | Crossref Full Text | Google Scholar

Reis da Silva T. (2024). Can supplementing vitamin B12 improve mental health outcomes?: a literature review. Br. J. Community Nurs. 29, 137–146. doi: 10.12968/bjcn.2024.29.3.137

PubMed Abstract | Crossref Full Text | Google Scholar

Rezende E. S. V., Lima G. C., and Naves M. M. V. (2021). Dietary fibers as beneficial microbiota modulators: A proposed classification by prebiotic categories. Nutrition 89, 111217. doi: 10.1016/j.nut.2021.111217

PubMed Abstract | Crossref Full Text | Google Scholar

Riazati N., Kable M. E., Newman J. W., Adkins Y., Freytag T., Jiang X., et al. (2022). Associations of microbial and indoleamine-2, 3-dioxygenase-derived tryptophan metabolites with immune activation in healthy adults. Front. Immunol. 13, 917966. doi: 10.3389/fimmu.2022.917966

PubMed Abstract | Crossref Full Text | Google Scholar

Rodrigues-Amorim D., Rivera-Baltanás T., Regueiro B., Spuch C., de Las Heras M. E., Vazquez-Noguerol Mendez R., et al. (2018). The role of the gut microbiota in schizophrenia: Current and future perspectives. World J. Biol. Psychiatry 19, 571–585. doi: 10.1080/15622975.2018.1433878

PubMed Abstract | Crossref Full Text | Google Scholar

Rodríguez J. M., Murphy K., Stanton C., Ross R. P., Kober O. I., Juge N., et al. (2015). The composition of the gut microbiota throughout life, with an emphasis on early life. Microb. Ecol. Health Dis 26, 26050. doi: 10.3402/mehd.v26.26050

PubMed Abstract | Crossref Full Text | Google Scholar

Romijn A. R., Rucklidge J. J., Kuijer R. G., and Frampton C. (2017). A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust. New Z. J. Psychiatry 51, 810–821. doi: 10.1177/0004867416686694

PubMed Abstract | Crossref Full Text | Google Scholar

Rusch J. A., Layden B. T., and Dugas L. R. (2023). Signaling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. Front. Endocrinol. 14, 1130689. doi: 10.3389/fendo.2023.1130689

PubMed Abstract | Crossref Full Text | Google Scholar

Rutsch A., Kantsjö J. B., and Ronchi F. (2020). The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front. Immunol. 11, 604179. doi: 10.3389/fimmu.2020.604179

PubMed Abstract | Crossref Full Text | Google Scholar

Sabina M., Zakhrokhon T., and Gulamovna D. B. (2024). Nervous system and its main functions. Eurasian J. Med. Natural Sci. 4, 61–67. doi: 10.5281/zenodo.10461159

Crossref Full Text | Google Scholar

Salminen A. (2023). Activation of aryl hydrocarbon receptor (AhR) in Alzheimer’s disease: Role of tryptophan metabolites generated by gut host-microbiota. J. Mol. Med. 101, 201–222. doi: 10.1007/s00109-023-02289-5

PubMed Abstract | Crossref Full Text | Google Scholar

Sanikhani N. S., Modarressi M. H., Jafari P., Vousooghi N., Shafei S., Akbariqomi M., et al. (2020). The effect of Lactobacillus casei consumption in improvement of obsessive–compulsive disorder: an animal study. Probiotics Antimicrob. Proteins 12, 1409–1419. doi: 10.1007/s12602-020-09642-x

PubMed Abstract | Crossref Full Text | Google Scholar

Sarkar A., Harty S., Johnson K. V. A., Moeller A. H., Carmody R. N., Lehto S. M., et al. (2020). The role of the microbiome in the neurobiology of social behaviour. Biol. Rev. 95, 1131–1166. doi: 10.1111/brv.12603

PubMed Abstract | Crossref Full Text | Google Scholar

Schmidt K., Cowen P. J., Harmer C. J., Tzortzis G., Errington S., and Burnet P. W. (2015). Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology 232, 1793–1801. doi: 10.1007/s00213-014-3810-0

PubMed Abstract | Crossref Full Text | Google Scholar

Scott S. A., Fu J., and Chang P. V. (2024). Dopamine receptor D2 confers colonization resistance via microbial metabolites. Nature 628, 180–185. doi: 10.1038/s41586-024-07179-5

PubMed Abstract | Crossref Full Text | Google Scholar

Shanmugam H., Ganguly S., and Priya B. (2022). Plant food bioactives and its effects on gut microbiota profile modulation for better brain health and functioning in Autism Spectrum Disorder individuals: A review. Food Front. 3, 124–141. doi: 10.1002/fft2.125

Crossref Full Text | Google Scholar

Sharma R., Gupta D., Mehrotra R., and Mago P. (2021). Psychobiotics: the next-generation probiotics for the brain. Curr. Microbiol. 78, 449–463. doi: 10.1007/s00284-020-02289-5

PubMed Abstract | Crossref Full Text | Google Scholar

Sharon G., Cruz N. J., Kang D.-W., Gandal M. J., Wang B., Kim Y.-M., et al. (2019). Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell 177, 1600–18. e17. doi: 10.1016/j.cell.2019.05.004

PubMed Abstract | Crossref Full Text | Google Scholar

Silva Y. P., Bernardi A., and Frozza R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front. Endocrinol. 11, 508738. doi: 10.3389/fendo.2020.00025

PubMed Abstract | Crossref Full Text | Google Scholar

Simpson C. A., Diaz-Arteche C., Eliby D., Schwartz O. S., Simmons J. G., and Cowan C. S. (2021). The gut microbiota in anxiety and depression–a systematic review. Clin. Psychol. Review 83, 101943. doi: 10.1016/j.cpr.2020.101943

PubMed Abstract | Crossref Full Text | Google Scholar

Singh S., Sharma P., Pal N., Kumawat M., Shubham S., Sarma D. K., et al. (2022). Impact of environmental pollutants on gut microbiome and mental health via the gut–brain axis. Microorganisms 10, 1457. doi: 10.3390/microorganisms10071457

PubMed Abstract | Crossref Full Text | Google Scholar

Skrzypczak-Wiercioch A. and Sałat K. (2022). Lipopolysaccharide-induced model of neuroinflammation: mechanisms of action, research application and future directions for its use. Molecules 27, 5481. doi: 10.3390/molecules27175481

PubMed Abstract | Crossref Full Text | Google Scholar

Slykerman R. F., Neumann D., Underwood L., Hobbs M., and Waldie K. E. (2023). Age at first exposure to antibiotics and neurodevelopmental outcomes in childhood. Psychopharmacology 240, 1143–1150. doi: 10.1007/s00213-023-06351-5

PubMed Abstract | Crossref Full Text | Google Scholar

Smith K. S., Greene M. W., Babu J. R., and Frugé A. D. (2021). Psychobiotics as treatment for anxiety, depression, and related symptoms: a systematic review. Nutr. Neurosci. 24, 963–977. doi: 10.1080/1028415X.2019.1701220

PubMed Abstract | Crossref Full Text | Google Scholar

Smith L. K. and Wissel E. F. (2019). Microbes and the mind: how bacteria shape affect, neurological processes, cognition, social relationships, development, and pathology. Perspect. psychol. Sci. 14, 397–418. doi: 10.1177/1745691618809379

PubMed Abstract | Crossref Full Text | Google Scholar

Stasi C., Sadalla S., and Milani S. (2019). The relationship between the serotonin metabolism, gut-microbiota and the gut-brain axis. Curr. Drug Metab. 20, 646–655. doi: 10.2174/1389200220666190725115503

PubMed Abstract | Crossref Full Text | Google Scholar

Steen E. H., Wang X., Balaji S., Butte M. J., Bollyky P. L., and Keswani S. G. (2020). The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis. Adv. Wound Care 9, 184–198. doi: 10.1089/wound.2019.1032

PubMed Abstract | Crossref Full Text | Google Scholar

Strle K., Zhou J.-H., Shen W.-H., Broussard S. R., Johnson R. W., Freund G. G., et al. (2001). Interleukin-10 in the brain. Crit. Rev. Immunol. 21, 427–450. doi: 10.1615/CritRevImmunol.v21.i5.20

Crossref Full Text | Google Scholar

Tan Q., Orsso C. E., Deehan E. C., Kung J. Y., Tun H. M., Wine E., et al. (2021). Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review. Autism Res. 14, 1820–1836. doi: 10.1002/aur.2560

PubMed Abstract | Crossref Full Text | Google Scholar

Taniya M. A., Chung H.-J., Al Mamun A., Alam S., Aziz M. A., Emon N. U., et al. (2022). Role of gut microbiome in autism spectrum disorder and its therapeutic regulation. Front. Cell. Infect. Microbiol. 12, 915701. doi: 10.3389/fcimb.2022.915701

PubMed Abstract | Crossref Full Text | Google Scholar

Tarkesh F., Namavar Jahromi B., Hejazi N., and Hoseini G. (2022). Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial. BMC Women's Health 22, 315. doi: 10.1186/s12905-022-01825-8

PubMed Abstract | Crossref Full Text | Google Scholar

Tavella T., Rampelli S., Guidarelli G., Bazzocchi A., Gasperini C., Pujos-Guillot E., et al. (2021). Elevated gut microbiome abundance of Christensenellaceae, Porphyromonadaceae and Rikenellaceae is associated with reduced visceral adipose tissue and healthier metabolic profile in Italian elderly. Gut Microbes 13, 1880221. doi: 10.1080/19490976.2021.1880221

PubMed Abstract | Crossref Full Text | Google Scholar

Tette F.-M., Kwofie S. K., and Wilson M. D. (2022). Therapeutic anti-depressant potential of microbial GABA produced by Lactobacillus rhamnosus strains for GABAergic signaling restoration and inhibition of addiction-induced HPA axis hyperactivity. Curr. Issues Mol. Biol. 44, 1434–1451. doi: 10.3390/cimb44040096

PubMed Abstract | Crossref Full Text | Google Scholar

Thabet E., Dief A. E., Arafa S. A., Yakout D., and Ali M. A. (2024). Antibiotic-induced gut microbe dysbiosis alters neurobehavior in mice through modulation of BDNF and gut integrity. Physiol. Behav. 283, 114621. doi: 10.1016/j.physbeh.2024.114621

PubMed Abstract | Crossref Full Text | Google Scholar

Thakur K., Tomar S. K., and De S. (2016). Lactic acid bacteria as a cell factory for riboflavin production. Microb. Biotechnol. 9, 441–451. doi: 10.1111/1751-7915.12335

PubMed Abstract | Crossref Full Text | Google Scholar

Turna J., Grosman Kaplan K., Anglin R., Patterson B., Soreni N., Bercik P., et al. (2020). The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age-and sex-matched controls: A pilot study. Acta Psychiatrica Scand. 142, 337–347. doi: 10.1111/acps.13175

PubMed Abstract | Crossref Full Text | Google Scholar

Turna J., Grosman Kaplan K., Anglin R., and Van Ameringen M. (2016). What's bugging the gut in OCD?” A review of the gut microbiome in obsessive–compulsive disorder. Depression Anxiety 33, 171–178. doi: 10.1002/da.22454

PubMed Abstract | Crossref Full Text | Google Scholar

Uebanso T., Shimohata T., Mawatari K., and Takahashi A. (2020). Functional roles of B-vitamins in the gut and gut microbiome. Mol. Nutr. Food Res. 64, 2000426. doi: 10.1002/mnfr.202000426

PubMed Abstract | Crossref Full Text | Google Scholar

Van Kessel S. P. and El Aidy S. (2019). Contributions of gut bacteria and diet to drug pharmacokinetics in the treatment of Parkinson's disease. Front. Neurol. 10, 1087. doi: 10.3389/fneur.2019.01087

PubMed Abstract | Crossref Full Text | Google Scholar

Vasiliu O. (2023). Is fecal microbiota transplantation a useful therapeutic intervention for psychiatric disorders? A narrative review of clinical and preclinical evidence. Curr. Med. Res. Opinion 39, 161–177. doi: 10.1080/03007995.2022.2124071

PubMed Abstract | Crossref Full Text | Google Scholar

Ventriglio A., Sancassiani F., Contu M. P., Latorre M., Di Salvatore M., Fornaro M., et al. (2020). Mediterranean diet and its benefits on health and mental health: a literature review. Clin. Pract. Epidemiol. Ment. Health: CP EMH 16, 156. doi: 10.2174/1745017902016010156

PubMed Abstract | Crossref Full Text | Google Scholar

Villageliú D. and Lyte M. (2018). Dopamine production in Enterococcus faecium: a microbial endocrinology-based mechanism for the selection of probiotics based on neurochemical-producing potential. PloS One 13, e0207038. doi: 10.1371/journal.pone.0207038

PubMed Abstract | Crossref Full Text | Google Scholar

Voigt R. M., Engen P. A., Villanueva M., Bambi S. A., Green S. J., Naqib A., et al. (2025). Prebiotics as an adjunct therapy for posttraumatic stress disorder: a pilot randomized controlled trial. Front. Neurosci. 18, 1477519. doi: 10.3389/fnins.2024.1477519

PubMed Abstract | Crossref Full Text | Google Scholar

Vuong H. E. and Hsiao E. Y. (2017). Emerging roles for the gut microbiome in autism spectrum disorder. Biol. Psychiatry 81, 411–423. doi: 10.1016/j.biopsych.2016.08.024

PubMed Abstract | Crossref Full Text | Google Scholar

Walther B. and Chollet M. (2017). Menaquinones, bacteria, and foods: vitamin K2 in the. Vitamin K2: Vital Health Wellbeing 63. doi: 10.5772/63712

Crossref Full Text | Google Scholar

Wang Y., Duan C., Du X., Zhu Y., Wang L., Hu J., et al. (2024). Vagus nerve and gut-brain communication. Neuroscientist, 10738584241259702. doi: 10.1177/10738584241259702

PubMed Abstract | Crossref Full Text | Google Scholar

Wang S.-T., He X.-Y., Le J., Sun T., and Peng R. (2024). Associations between vitamin K and suicide attempts in patients with depression: a case-control study. J. Inflammation Res., 3423–3431. doi: 10.2147/JIR.S463204

PubMed Abstract | Crossref Full Text | Google Scholar

Wang Z., Yuan X., Zhu Z., Pang L., Ding S., Li X., et al. (2024). Multiomics analyses reveal microbiome–gut–brain crosstalk centered on aberrant gamma-aminobutyric acid and tryptophan metabolism in drug-naïve patients with first-episode schizophrenia. Schizophr. Bull. 50 (1), 187–198. doi: 10.1093/schbul/sbad026

PubMed Abstract | Crossref Full Text | Google Scholar

Wiley N. C., Dinan T., Ross R., Stanton C., Clarke G., and Cryan J. (2017). The microbiota-gut-brain axis as a key regulator of neural function and the stress response: Implications for human and animal health. J. Anim. Sci. 95, 3225–3246. doi: 10.2527/jas.2016.1256

PubMed Abstract | Crossref Full Text | Google Scholar

Winder C., Lodhia A., Basso M., and Cohen Kadosh K. (2025). Gut microbiome differences in individuals with PTSD compared to trauma-exposed controls: a systematic review. Front. Neurosci. 19, 1540180. doi: 10.3389/fnins.2025.1540180

PubMed Abstract | Crossref Full Text | Google Scholar

Wu Q., Xu Z., Song S., Zhang H., Zhang W., Liu L., et al. (2020). Gut microbiota modulates stress-induced hypertension through the HPA axis. Brain Res. Bull. 162, 49–58. doi: 10.1016/j.brainresbull.2020.05.014

PubMed Abstract | Crossref Full Text | Google Scholar

Xu J., Patassini S., Begley P., Church S., Waldvogel H. J., Faull R. L., et al. (2020). Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer’s disease. Biochem. Biophys. Res. Commun. 527, 676–681. doi: 10.1016/j.bbrc.2020.05.015

PubMed Abstract | Crossref Full Text | Google Scholar

Xu Y., Xiang S., Ye K., Zheng Y., Feng X., Zhu X., et al. (2018). Cobalamin (vitamin B12) induced a shift in microbial composition and metabolic activity in an in vitro colon simulation. Front. Microbiol. 9, 2780. doi: 10.3389/fmicb.2018.02780

PubMed Abstract | Crossref Full Text | Google Scholar

Yadav S. K., Ahmad R., Moshfegh C. M., Sankarasubramanian J., Joshi V., Elkhatib S. K., et al. (2023). Repeated social defeat stress induces an inflammatory gut milieu by altering the mucosal barrier integrity and gut microbiota homeostasis. Biol. Psychiatry Global Open Sci. 3, 824–836. doi: 10.1016/j.bpsgos.2023.03.005

PubMed Abstract | Crossref Full Text | Google Scholar

Yan F., Xia L., Xu L., Deng L., and Jin G. (2022). A comparative study to determine the association of gut microbiome with schizophrenia in Zhejiang, China. BMC Psychiatry 22, 731. doi: 10.1186/s12888-022-04328-w

PubMed Abstract | Crossref Full Text | Google Scholar

Ye Z., Gao Y., Yuan J., Chen F., Xu P., and Liu W. (2025). The role of gut microbiota in modulating brain structure and psychiatric disorders: A Mendelian randomization study. NeuroImage, 121292. doi: 10.1016/j.neuroimage.2025.121292

PubMed Abstract | Crossref Full Text | Google Scholar

Ye X., Li H., Anjum K., Zhong X., Miao S., Zheng G., et al. (2022). Dual role of indoles derived from intestinal microbiota on human health. Front. Immunol. 13, 903526. doi: 10.3389/fimmu.2022.903526

PubMed Abstract | Crossref Full Text | Google Scholar

Yoo J. Y., Sarkar A., Song H.-S., Bang S., Shim G., Springer C., et al. (2025). Gut microbiome alterations, mental health, and alcohol consumption: investigating the gut–brain axis in firefighters. Microorganisms 13, 680. doi: 10.3390/microorganisms13030680

PubMed Abstract | Crossref Full Text | Google Scholar

Zeng C., Qiu Y., Li S., Teng Z., Xiang H., Chen J., et al. (2022). Effect of probiotic supplements on oxidative stress biomarkers in first-episode bipolar disorder patients: a randomized, placebo-controlled trial. Front. Pharmacol. 13, 829815. doi: 10.3389/fphar.2022.829815

PubMed Abstract | Crossref Full Text | Google Scholar

Zhang H., Li M., Mo L., Luo J., Shen Q., and Quan W. (2023). Association between western dietary patterns, typical food groups, and behavioral health disorders: an updated systematic review and meta-analysis of observational studies. Nutrients 16, 125. doi: 10.3390/nu16010125

PubMed Abstract | Crossref Full Text | Google Scholar

Zhang Y.-D., Shi D.-D., Liao B.-B., Li Y., Zhang S., Gao J., et al. (2024). Human microbiota from drug-naive patients with obsessive-compulsive disorder drives behavioral symptoms and neuroinflammation via succinic acid in mice. Mol. Psychiatry 29, 1782–1797. doi: 10.1038/s41380-024-02424-9

PubMed Abstract | Crossref Full Text | Google Scholar

Zhao N., Shu Y., Jian C., Zhou Z., Bao H., Li X., et al. (2022). Lactobacillus ameliorates SD-induced stress responses and gut dysbiosis by increasing the absorption of gut-derived GABA in rhesus monkeys. Front. Immunol. 13, 915393. doi: 10.3389/fimmu.2022.915393

PubMed Abstract | Crossref Full Text | Google Scholar

Zhao N. O., Topolski N., Tusconi M., Salarda E. M., Busby C. W., Lima C. N., et al. (2022). Blood-brain barrier dysfunction in bipolar disorder: molecular mechanisms and clinical implications. Brain Behav. Immun. Health 21, 100441. doi: 10.1016/j.bbih.2022.100441

PubMed Abstract | Crossref Full Text | Google Scholar

Zheng P., Zeng B., Liu M., Chen J., Pan J., Han Y., et al. (2019). The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviours in mice. Sci. Adv. 5, eaau8317. doi: 10.1126/sciadv.aau8317

PubMed Abstract | Crossref Full Text | Google Scholar

Zhou P., Chen C., Patil S., and Dong S. (2024). Unveiling the therapeutic symphony of probiotics, prebiotics, and postbiotics in gut-immune harmony. Front. Nutr. 11, 1355542. doi: 10.3389/fnut.2024.1355542

PubMed Abstract | Crossref Full Text | Google Scholar

Zou R., Xu F., Wang Y., Duan M., Guo M., Zhang Q., et al. (2020). Changes in the gut microbiota of children with autism spectrum disorder. Autism Res. 13, 1614–1625. doi: 10.1002/aur.2358

PubMed Abstract | Crossref Full Text | Google Scholar